AP 2019 Invited Speakers

Tania Ahmed

 

bio

Tania Ahmed is a biomaterials technical leader at the Medical Devices Branch of the Therapeutic Goods Administration (TGA). She has over six years of experience as a regulatory scientist in the TGA where she is heavily involved in the assessment of high risk medical devices and emerging technologies to ensure they are safe for supply in Australia. Tania received her Bachelor of Medical Sciences (Hons) and PhD degrees from the University of New South Wales, and has considerable experience in areas of developing novel biomaterials for tissue engineering applications.

Behnam Akhavan

 

bio

Sandanori Akita

Adipose-Detived Stem Cells successfully Treat Rat HIndlimb Ischemia

 

bio

Dr. Akita is currently a professor-in-chief of department of plastic surgery, wound repair and regeneration of Fukuoka University, Faculty of Medicine and he did his residency in plastic surgery at Nagasaki University Hospital. He received his PhD from the Graduate School of Nagasaki University specializing in plastic and reconstructive surgery. He later did a research fellowship at Cedars-Sinai Medical Center, University of California, Los Angeles (UCLA) under supervision of Shlomo Melmed MD on a cytokine expression and its regulation in vivo by using a transgenic animal model. He serves as a general secretary of World Union of Wound Healing Societies, which will be held in Yokohama, September 2-6, 2012, http://wuwhs2012.com/ and will be president of the world union of wound healing societies, for the years of 2012 to 2016. He is the president of the World Union of Wound Healing Societies (WUWHS) from September, 2012 to September, 2016 and currently the president of the Asian Wound Care Association (AWCA). His research interests include: cytokines and stem cells in wound healing, difficult wound healing (radiation injury), regenerative tissue enhancement to HIV-drug related-wasting patients, reconstructive surgery, burn, craniofacial surgery and hemangioma/vascular malformations.
His list of publications include 100 peer-reviewed English original articles, 25 English overviews and 20 English-book chapters with 7 editorship of the books and lead the two study sectors funded by the Ministry of Health, Labor and Welfare on vascular anomaly and on cybernic medicine.

Sultan Al-Maskari

Femur bone tissue engineering using 3D Printed scaffolds

 

bio

Dr Sultan Al Maskari received his BSc (Medical Sciences) from St Andrews University, Scotland and completed his MBChB at Glasgow University, Scotland in 1990. Following completion of his orthopaedic training in Mersey Deanery, England, he returned to his home country, Oman in 2002. He established & led the limb reconstruction unit at Khoula Hospital, Muscat until 2008. He moved to Sultan Qaboos University Hospital (SQUH) to establish the orthopaedic service which he is still heading, currently. His clinical interests focus on the lower limb, including reparative & reconstructive techniques in addition to arthroplasty & complex trauma. He has special interest in bone & joint preservation and regeneration. He has been using autologous tissue regenerative techniques for many years. Recently he has used bioresorbable bioactivated custom made 3D printed synthetic scaffolds to treat large segmental long bone defects. He is keen on close interdisciplinary collaboration and cooperation in this field.

Ben Allardyce

 

bio

Ben is a Research Fellow at the Institute for Frontier Materials (IFM) at Deakin University. His research focuses on the development of silk based biomaterials, particularly for use in the middle ear. Ben holds a PhD in biochemistry, with a focus on crustacean digestive cellulases. He joined IFM in 2012, working on a project to develop silk based membranes to repair chronic perforations of the tympanic membrane. This project, a collaboration between Deakin and the Ear Science Institute Australia, is currently progressing towards human clinical trial. Ben’s other work involves harnessing the exceptional properties of silk fibroin to enhance the performance of a range of biomaterials, from silk reinforced hydrogel inks for bioprinting to microfibrillated silk “paper” scaffolds.

Mark Allenby

 

bio

Andrejs Atrens

 

bio

Atrens is Professor of Materials at The University of Queensland (UQ), where he has been since 1984. He was awarded DEng (a higher doctorate) in 1997 by UQ, and became Fellow of the Higher Education Academy in 2018.
An international academic reputation is evident from invitations for keynote papers at international conferences (25 since 2004), invitations as guest scientist/visiting professor at leading international laboratories (in China, Switzerland, Germany, Belgium, France & Sweden, 27 months since 2003), a ISI H-index of 54 [web of science] (66 [Google scholar]), many citations (13,610 citations [web of science]; 19,094 [Google scholar]), 23 journal papers with more than 100 citations, 10 journal papers with more than 200 citations, and an excellent publication record in top international journals with more than 280 refereed journal publications. Research areas are: corrosion of magnesium, stress corrosion cracking, corrosion mechanisms, atmospheric corrosion and patination of copper. In the last 5 years since 2013 Atrens has published 83 refereed journal publications.

Atrens has made significant contributions to the understanding of the service performance of engineering materials. This includes:
• Understanding of influence of hydrogen in steels, including advanced high-strength steels for auto construction,
• Elucidated corrosion mechanisms of magnesium alloys, stainless steels and copper alloys,
• Developed a model for the patination of copper, and a procedure for an artificial patination process,
• Developed an improved understanding of passivity in stainless steels and binary alloys such as Fe-Cr, Ni-Cr, Co-Cr, Fe-Ti, and Fe-Si.
Contributions to the understanding of magnesium corrosion include:
• Characterised the corrosion reactions, types of corrosion and the corrosion morphologies for Mg alloys and related these to alloy chemistry, metallurgy and microstructure.
• Help to provide an understanding of the biocorrosion of Mg.
• Produced a comprehensive explanation of the strange electrochemical behaviour of the negative difference effect, which underlies the corrosion behaviour of magnesium and its alloys.

Akash Bachhuka

 

bio

Dr Akash Bachhuka completed his PhD with Prof. Krasimir Vasilev at the Mawson Institute, University of South Australia in 2015. His thesis investigated the effect of different chemistry and nanotopography on cell-surface interaction. He is now a Research Associate at ARC Centre of Excellence for Nanoscale BioPhotonics, Institute for Photonics and Advanced Sensing, School of Physical Sciences, University of Adelaide, Australia. His current research focuses on bio sensing and metal ion sensing using microstructured optical glass fibers.

Elizabeth Rosado Balmayor

Growth factor delivery for bone tissue engineering using RNA

 

bio

Elizabeth Rosado Balmayor is 41 years old and was born in Havana, Cuba. Her educational background includes a BSc in chemistry and a MSc in Materials Science and Technology awarded by the University of Havana. In 2005, she was granted with an Alea Jacta EST PhD scholarship in the frame of the EXPERTISSUES Network of Excellence. This allowed her to perform her PhD studies in Materials Science and Technology - Biomaterials at the world-renowned “3Bs” Research Group (University of Minho, Portugal) under the supervision of Prof. Rui Reis. To deepen her knowledge in the gene therapy field, she moved to the Technical University of Munich - TUM, Germany where she has been working for the last six years on gene therapy for musculoskeletal regeneration. A powerful breakthrough in Elizabeth’s research is the development of a chemically modified mRNA as an alternative to traditional gene therapy for bone healing. Elizabeth holds a patent on this discovery, which serves as the basis for the start-up company Ethris GmbH. Since 2016, Elizabeth is Assistant Professor for Experimental Trauma Surgery at the TUM. She has published 52 peer reviewed original papers, 7 book chapters and has 2 patents. She has received several awards for her work, among others the Hans-Liniger award presented to young scientists for outstanding achievements in the field of traumatology from the German Trauma Society. She serves currently on the council of EORS as ex-oficio Female Leadership Representative chair.

Michal Bartnikowski

 

bio

Dr Michal Bartnikowski is a postdoctoral research fellow at The University of Queensland (UQ) School of Dentistry. He graduated with first class honours from Biomedical Engineering at the Queensland University of Technology (QUT) in 2011, and completed his PhD over the period of 2012 – 2015. After the completion of his PhD, Dr Bartnikowski spent 18 months working at Vaxxas, a company developing a micro-needle array patch for injection-free vaccination. In this role at a rapidly moving start-up, he gained experience in quality management and furthered his understanding of regulatory requirements.
He returned to research in January of 2017 to join Professor Saso Ivanovski’s team, coordinating the 3D printing of the group, pursuing clinical translation of scaffold technologies, and the development of novel biomaterials. Dr Bartnikowski has worked with 3D printing technologies since 2011, when he was involved in the development and optimisation of the first biomaterial 3D printer at QUT. He has worked extensively with numerous 3D printing platforms and technologies, as well as with the development of a range of thermoplastic and hydrogel polymers. Dr Bartnikowski is a specialist biomaterial scientist and medical engineer, with industry-leading knowledge in the area of 3D printing of thermoplastic polymers.

Onur Bas

 

bio

Frank Beier

 

bio

Frank Beier is the Canada Research Chair in Musculoskeletal Research at the University of Western Ontario and a member of Western’s Bone and Joint Institute. He is a Professor and Chair of the Department of Physiology and Pharmacology. His lab explores mechanisms controlling cartilage and joint biology, using genomic approaches and genetically engineered mice in combination with surgical, dietary and activity manipulations. Dr. Beier has published over 120 peer-reviewed articles and gave more than 100 invited presentations. His work is supported by the Canadian Institutes of Health Research. He was a member of the Board of Directors of the Osteoarthritis Research Society International (OARSI) and is a current member of the Faculty of 1000 and several editorial boards, including the Deputy Editor for Osteoarthritis & Cartilage. He was the Chair of the 2017 Cartilage Gordon Conference and was awarded the Basic Science Award from OARSI in 2019.

Liming Bian

Self-assembled injectable nanocomposite hydrogels for tissue engineering

 

bio

Dr. Bian Liming is currently an associate professor in the Department of Biomedical Engineering at the Chinese University of Hong Kong. Dr. Bian completed his Ph.D. study in Biomedical Engineering at Columbia University in 2009. Dr. Liming Bian then conducted his postdoctoral research in the Department of Bioengineering, the University of Pennsylvania from 2009 to 2012. In 2012, Dr. Bian joined the Chinese University of Hong Kong as an assistant professor. Dr. Bian’s research focuses on the development of novel multiscale biomaterials not only for investigating the role of cell microenvironment factors on stem cell behaviors but also for facilitating the regeneration of diseased or injured tissues and organs. Dr. Bian’s research work has been published in the leading journals including PNAS, JACS, Nano Letters, Biomaterials, Nature Communications, Advanced Materials, Advanced Functional Materials, Advanced Science, ACS Nano, Macromolecules, ACS Central Science, Chemistry of Materials.

Marcela Bilek

 

bio

Oliver Bissinger

Angiogenesis and bone regeneration by using bioactive biodegradable scaffolds

 

bio

Oliver Bissinger studied Medicine and Dentistry in Munich, Germany and in Sydney, Australia. In 2008, he started as a resident at the Department of Oral and Maxillofacial Surgery, "Klinikum Rechts der Isar", Technical University Munich. In the context of his medical (MD) and dental (DDS) doctoral theses, he used imaging and laboratory modalities to assess bone regeneration after application of (the genetic information) rhBMP-2 or different drugs in the rat. In 2015, he worked at the CSIRO for research in terms of scaffolds and RAFT polymerisation. In the same year, he also became specialist for oral- and maxillofacial surgery and consultant. In 2017, he achieved the designation 'plastic operations'. In 2018, he became fellow of the European Board of Oral-Maxillo-Facial-Surgery, Head and Neck Surgery (FEBOMFS) and finished his PhD and got the 'venia legendi'. In this context, he designs teaching courses and holds lectures. His main research includes the assessment of the influence of a polymer based therapy (RAFT polymerisation) aimed at transfection and expression of BMP-2. In this context, biodegradable scaffolds are investigated in vivo (rat critical-size-defect-models) in regard to its osteogenic/antiinfective properties. Bone and blood vessels are examined simultaneously by using microCT and IHC. The role of BMP-2 is also evaluated on protein and RNA level. In this context, he achieved a third party funded project of the higly reputed DFG (German Research Foundation) as an exclusive first applicant. He has published 26 peer reviewed original papers with more than 194 citations and reached a H-index of 7.

Laura Bray

 

bio

Christopher Breuer

Cardiovascular Tissue Engineering for Use in Congenital Heart Surgery

 

bio

Director of Regenerative Medicine, Nationwide Children's Hospital
Pediatric Surgeon, Nationwide Children's Hospital

Karl Brown

Proliferative capacity of corneal endothelial progenitor cell spheres

 

bio

Dr Karl Brown is a Research Fellow at the Centre for Eye Research Australia. In 2016 he was the Inaugural Lions' Corneal Research Fellow. Karl has a background in molecular and developmental biology. A NHMRC Dora Lush Scholarship funded his PhD from the University of Melbourne in the field of corneal tissue engineering. Though only three years post-PhD, Karl has given seven international oral presentations including invited talks in China, Taiwan, and at Moorfields. He is a regular speaker at the ANZ Cornea Society. He is currently continuing his work on the cornea at CERA where he works closely with the Lions Eye Donation Service and University Departments of Veterinary Science and Chemical Engineering.

Subhas C. Kundu

Biomimetic biomaterials for in vitro cancer microenvironment modeling

 

bio

Subhas C. Kundu is now European Research Area Chair and Professor, 3Bs Research Group, I3Bs – Institute on Biomaterials, Biodegradables and Biomimetics of University of Minho, Portugal since September 01, 2016. Earlier Dr. Kundu was Professor at Department of Biotechnology, Indian Institute of Technology Kharagpur. He obtained his Post-graduation and Ph. D in genetics from Banaras Hindu University, India and received his Post-doctoral trainings at Institute of Molecular Biology, Moscow; York University, Canada; Medical University, Lubeck, Germany and Brunel University, UK. His research interest had has been with silk biomaterial matrices for biomedical applications including 3D cancer modelling for investigating the tumor growth, proliferation and drug screening. Editorial board members: Biomaterials, Biomedical Materials, Journal of Biological Engineering and others. He has published 174 research articles in peer-reviewed journals like Journal of Biological Chemistry, Biomaterials, Biotechnology and Bioengineering, Acta Biomaterialia, Progress in Polymer Science, Biotechnology Advances, Bio-macromolecules, Advanced Functional Materials, Advanced Materials and others. Present area of interest is natural biomaterials for 3D cancer modelling for drug screening.

Sandra Camarero-Espinosa

Self-assembled biomaterials to control cell fate

 

bio

Sandra Camarero-Espinosa was educated at the University of the Basque Country (Spain) where she obtained her BSc. degree as Chemical Engineer and M.Sc. in Engineering of Advanced Materials. She then moved to Switzerland where she developed her doctoral studies under the supervision of Profs. Johan Foster and Christoph Weder, at the Adolphe Merkle Institute(Fribourg, Switzerland). On 2015, Sandra obtained her PhD degree in Polymer Chemistry and Bioengineering and was recognized with an award to an outstanding PhD thesis by the Swiss Chemical Society. After gaining a fellowship from the Swiss National Science Foundation, she moved to Brisbane (Australia) to work at the Australian Institute for Bioengineering and Nanotechnology with Prof. Cooper-White. Here, she continued her research on instructive biomaterials scaffolds and their interaction with stem cells for cartilage tissue engineering. Sandra is now a post-doctoral researcher at the MERLN institute where she works on the development of instructive hierarchical biomaterial scaffolds for the regeneration of complex tissues. Sandra's research interests revolve around the regeneration of complex tissues. The design, synthesis, fabrication and investigation of novel hierarchical polymeric bio(nano)materials whose physicochemical properties can be tuned mimicking nature from the molecular to the macro scale and, the effect of these ones on cell phenotype and matrix deposition are the focus of her research. In particular, the spatial control of chemical and
structural properties at the nanoscale that affect the overall functionality of the neo-tissue and their distribution in well-organized 3-dimensional structures.

Hyung Joon Cha

 

bio

Park Chan hum

 

bio

Dr. Chan Hum Park was born in 1969 in Korea(South), I graduated the Hallym Univsersity Medical School(M.D.) in 1996. He obtained Ph.D. degree from KangWon National University, Korea. I have been working in chief(professor) of the department of Otorhinolaryngology Head & Neck Surgery in Chunchon Sacred Heart Hospital of Hallym Medical Center and Nano Bio Regenerative Medical Institute of Hallym University. My major study’s field of clinical part is the cancer surgery and reconstruction such as rhinoplasty, facial trauma, skin cancer etc. I founded the Nano Bio Regenerative Medical Institute. I developed the artificial dermis, tympanic membrane, absorbable fixation plate, artificial bone, and bioink materials using electrospinning, Bio 3D pririnting etc. And I developed the world’s first artificial tympanic membrane from silk fibroin and achieved the KFDA’s approval and commercialization in 2012. Nowadays, I have focused on stem cell and 3D printing for regenerative medicine and tissue engineering. I am a board member of Tissue Engineering and Regenerative Medicine International Society, Society for Biomaterials, World rhinologic society. I have co-authored or edited 9 books and 31 patents and published over 180 original research papers related in this field.

Fa-ming Chen

Biomaterials for endogenous regenerative medicine: coaxing stem cell homing and beyond

 

bio

Prof. Fa-Ming Chen is the director of the Department of Periodontology at the School of Stomatology and group leader of the Biomaterials Unit at the State Key Laboratory of Military Stomatology, Fourth Military Medical University (FMMU). He received his Ph.D. from the School of Stomatology FMMU in 2006 and has been a professor in the Department of Periodontology since 2007. His current research interests primarily involve the development of extracellular matrix (ECM)-mimicking materials based on biomimetic design and co-signaling between biophysical and biochemical ECM parameters for tissue engineering and endogenous tissue regeneration.

Guoping Chen

Dexamethasone-loaded biphasic calcium phosphate nanoparticles/collagen composite scaffolds for osteogenic differentiation of MSCs

 

bio

Prof. Guoping Chen received his Ph.D. from Kyoto University in 1997 majoring in Biomaterials and did postdoctoral research until 2000. He became Researcher in 2000 and Senior Researcher in 2003 at Tissue Engineering Research Center, National Institute for Advanced Industrial Science and Technology, Japan. He moved to Biomaterials Center, National Institute for Materials Science (NIMS) as Senior Researcher in 2004 and was promoted to Group Leader in January, 2007. He was Principal Investigator and Unit Director of Tissue Regeneration Materials Unit from April, 2011 to March, 2015; Principal Investigator, Field Coordinator and Unit Director of International Center for Materials Nanoarchitectonics, NIMS from April, 2015 to March, 2017. He is also Professor of Department of Materials Science and Engineering, Graduate School of Pure and Applied Science, University of Tsukuba, Japan. His research interests include tissue engineering, polymeric porous scaffolds, nanobiomaterials, biomimetic biomaterials, nano/micro-patterning and surface modification. He has authored more than 280 publications and holds 18 issued patents. He has given more than 140 invited lectures at conferences. He is Associate Editor of Journal of Materials Chemistry B; Editorial Boards of Journal of Bioactive and Compatible Polymers, Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Regenerative Biomaterials and Biomedical Materials; Advisory Board of Biomaterials Science. He also serves as Member-at-Large of Tissue Engineering and Regenerative Medicine International Society’s Asian-Pacific Chapter and Director of Japanese Society for Biomaterials. He has been selected Fellow of the Royal Society of Chemistry in 2015 and the American Institute for Medical and Biological Engineering (AIMBE) in 2017.

Jiansu Chen

 

bio

Dr Jiansu Chen has worked in the ophthalmology laboratory since obtaining her PhD degree in 1998. From then on, she teaches ophthalmology courses and participates in ophthalmic clinic. Her research direction is precision regenerative medicine for the repair of ocular damage using technology and means in tissue engineering, stem cells, RNA-Seq, bioinformatics analysis, CRISPR/Cas9 gene editing, molecular biology, genetics, and so on. At present, her team is going on the research on 3D bioprinting cornea and other ocular tissues using biomimetic approach, such as microgravity and perfusion culture, spheroid and layer by layer printing technology. Her team is doing research on induction of retinal pigment epithelial cells (RPE), retinal progenitor cells (RPC) and corneal endothelial cells from iPS cells. In addition, her team also do research on generation of iPS cells using urine-derived cells from patients with retinitis pigmentosa, retinoschisis and other retinopathy patients. There are doing the work on gene therapy in iPS cells derived retinal organoids from retinopathy patients.

Zetao Chen

The immunomodulatory property of collagen membrane and its manipulation

 

bio

Zetao Chen
BDSc, MDSc, Phd
ACADEMIC QUALIFICATION:
1. Bachelor of Dentistry (Majored in Dentistry, Supervisor: Zhuofan Chen), Sep. 2005 - June 2010, Sun Yat-sen University, North Campus, Guanghua School of Stomatology, Guangzhou, China.
2. Master of Dentistry (Majored in Oral Implantology, Supervisor: Zhuofan Chen), Sep.2010 - June 2012, Sun Yat-sen University, North Campus, Guanghua School of Stomatology, Guangzhou, China.
Research thesis: Studies of porcine hydroxyapatite in the solubility and MG63 adhesion properties
4. Doctor of Philosophy (Supervisors: Yin Xiao, Travis Klein, Ross Crawford), Sep.2012-Dec. 2015, Queensland University of Technology, Brisbane, Australia
5. Research Associate in Institute of Health and Biomedical Innovation, Queensland University of Technology, July2015- Oct. 2016
6. Associate Professor in Institute of Stomatological Research, Guanghua School of Stomatology, Sun Yat-sen University, Nov. 2016 - Feb. 2018
7. Professor in Institute of Stomatological Research, Guanghua School of Stomatology, Sun Yat-sen University, Feb. 2018-

Zhuofan Chen

 

bio

Dr. Chen is presently professor at Guanghua School of Stomatology, Sun Yat-sen University and also the vice director of the department of Dental Implantology. He obtained his Bachelor of Dental Science (BDSc) degree at Sun Yat-sen University of Medical Sciences (SUMS) in 1993, and achieved his Ph.D. degree at the University of Hong Kong at 2002. He now also serves as Co-Supervisor of Ph.D Program (Dental Material) of University of Hong Kong, and the visiting associate professor of the University of British Columbia.
Dr. Chen is the vice president of Chinese Society of Oral Implantology, the president of Guangdong Society of Oral Implantology, the committee board member of Australia-Chinese Center of Tissue Engineering & Regenerated Medicine, the fellow of International Team for Implantology, and the vice president of Hong Kong Society of Oral Implantology. Dr. Chen’s research focuses on clinical research of dental implant and bone regeneration materials, particularly those involving physicochemical properties, and tissue-cell interaction to biomaterials. He had been the chief investigator on 10 research grants (3 National Natural Science Foundation of China and 7 from Province or Ministry). Until now, he had published 37 SCI articles and 3 books. He is the editorial board member of the Journal of Chinese Stomatological Research, and the Implant Dentistry.

Nai-Chen Cheng

 

bio

Dr. Nai-Chen Cheng is a board-certified plastic surgeon in Taiwan. Clinically, he specializes in breast aesthetic and reconstructive surgery and treatment of difficult wounds. He has been the only two-time winner of the Best Reconstructive Save Award issued by Taiwan Society of Plastic Surgery. His research has been focused on applying adipose-derived stem cells in regenerative medicine, particularly wound healing. His team has investigated the biomaterial-assisted and scaffold-free 3D culture techniques to enhance the regenerative capabilities of adipose-derived stem cells. The series of study have been published in several first-tier journals, including Biomaterials, Acta Biomaterialia, Tissue Engineering and Stem Cells Translational Medicine. In 2016, Dr. Cheng was invited to give a speech in the annual conference of American College of Surgeons and received the International Guest Scholar Award. As a surgeon scientist, Dr. Cheng had been awarded the Career Development Grant from National Health Research Institutes, Taiwan. He also received the Dean Chen-Yuan Lee’s Memorial Award, National Taiwan University College of Medicine in 2018. Currently, Dr. Cheng serves as the Secretary-General of Formosa Association of Regenerative Medicine and a Director of Taiwan Society for Wound Care.

Sing Yan Chew

 

bio

Dr. Sing Yian CHEW is an Associate Professor at School of Chemical & Biomedical Engineering and Lee Kong Chian School of Medicine at Nanyang Technological University (NTU), Singapore. She is known for her contributions in designing biomimetic scaffolds to understand and control cell fate. Dr. Chew’s most significant contribution is in the field of scaffold-mediated delivery of gene-silencing and biomimicking physical signals for neural tissue regeneration and remyelination. Specifically, her lab engineers bio-functional platforms for long-term delivery of biologics. These scaffolding constructs may be used for understanding and directing neural tissue regeneration after traumatic injuries, stem cell fate and host-implant integration.

Since joining NTU, Dr. Chew has continued to embark on scientific learning and exchanges by serving as visiting scholar/professor at Johns Hopkins University, University of Edinburgh, INSERM (U698 and U791); University of Paris 13; University of Nantes; Jinan University in Guangzhou, China; Wyss Institute at Harvard. She also serves as the editorial board member in Journal of Biomedical Materials Research, Part A, Drug Delivery and Translational Research, Experimental Neurology and Journal of Tissue Engineering. Dr. Chew’s professional experience also includes evaluating research grants for local and international funding bodies, such as the Research Grant Council of Hong Kong, Netherlands Organisation for Scientific Research, German Research Foundation.

Hsin-Cheng Chiu

Dual Targeted Polysaccharide/Lipid Nanoparticles for Oral Combination Therapy Delivery against Colon Cancer

 

bio

Dr. Chiu received his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah in 1994. After serving as a faculty member in the Department of Chemical Engineering at National Chung Tsing University for 15 years, he moved to National Tsing Hua University in 2009. Dr. Chiu has a professional background in design, synthesis and development of stimuli-responsive supramolecular nanoconstructs for targeted delivery and controlled release of therapeutics. His current interests concentrate on exploiting smart nanomedicines for cancer theranostic applications and using tumortropic immune/stem cells as Trojan vehicles to deliver therapeutics and diagnostics to tumors that are more difficult to be treated with conventional nanomedicine delivery approaches. He has published many peer-reviewed research articles in renowned journals, such as Angewandte Chemie, Advanced Functional Materials, Biomaterials, Journal of Controlled Release and Macromolecules, etc. Dr. Chiu has also received many awards.

Seung-Woo Cho

 

bio

Seung-Woo Cho is a Professor at the Department of Biotechnology at Yonsei University, Republic of Korea. He obtained his B.S, M.S, and Ph.D. degrees in Chemical Engineering from Seoul National University in 1999, 2001, and 2006, respectively. He received his postdoctoral training at the Department of Chemical Engineering at the Massachusetts Institute of Technology. He later joined Yonsei University as a faculty member in 2010 and was awarded the 9th Asan Award for Young Medical Scientists in 2016. His research interests include stem cell engineering, reprogramming, and tissue engineering with functional biomaterials and biomedical devices. He has published 135 peer-reviewed papers and 28 pending/filed patents.

James Goh Cho Hong

Enhancing Enthesis using Silk-based Constructs

 

bio

Prof James GOH obtained his PhD Bioengineering (1982) from the University of Strathclyde, UK. He is Professor and Head, Department of Biomedical Engineering, National University of Singapore (NUS) and holds a joint appointment in the Orthopaedic Surgery, NUS. Prof Goh is on a number of national as well as international committees. He is the President of the International Union of Physical and Engineering Sciences in Medicine (IUPESM) as well as the Past-President of the International Federation of Medical and Biological Engineering (IFMBE) and the President of the Biomedical Engineering Society (Singapore). He is Fellow of the Institute of Engineers, Singapore (IES) and chairs IES’ Technical Committee on Biomedical Engineering. He is also a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) as well as Fellow of the ASEAN Academy of Engineering and Technology (AAET). Prof Goh is a Life Member of the World Association of Chinese Biomedical Engineers (WACBE). He chairs the Science and Technology Advisory Board of the Singapore Sports Institute. He is a member of the Biomedical and Health Standards Committee (BHSC), Singapore Standards Council and chairs the Technical Committee on Medical Devices. He chaired the World Congress of Biomechanics (2010), TERMIS-AP (2011) and ICBME (2015). Prof Goh has a strong research interest in musculoskeletal research and actively promotes the field of biomedical engineering. He has given numerous invited talks at international and regional conferences. He has published well over 150 international peer review journal papers, more than 500 conference papers and 12 book chapters.

Mark Chong

The MiMiC Platform: An engineered bone models of cancer metastasis and potential for translation

 

bio

Wojciech Chrzanowski

The Proteic and Vesicular Secretome of Cells in Regenerative Medicine

 

bio

Professor Wojciech Chrzanowski is a Deputy Director at Sydney Nano Institute and Head of Nanomedicine and Nano-Bio-Characterisation laboratory in the Sydney School of Pharmacy. He is a biomedical engineer who translates the science of extracellular vesicles and bio-characterisation at nanoscale to human applications. His work addresses a desperate need for effective technologies that regulate stem cells to promote desired tissue repair. Wojciech laboratory pioneers the use of nanoscale characterisation techniques to understand cellular communication and functionality of tissues. Wojciech contribution to the field is exemplified by over 140 peer-reviewed publications, four patents and over 50 invited talks and seminars. Translation potential of his work is demonstrated by several grant funding he received to move his research discoveries into realms of mainstream medicine.

Gianluca Ciardelli

 

bio

Gianluca Ciardelli (Ph.D) has a Master Degree in Chemistry summa cum laude, from the University of Pisa (1994). In 1997 he received the PhD in Natural Sciences from the Swiss Federal Institute of Technology (ETH) of Zurich on synthetic degradable polyurethanes for biomedical applications.

From 2002 and 2004 he was assistant professor at the University of Pisa at the Department of Chemical Engineering, Industrial Chemistry, Materials Science. In December 2004 he joined the Department of Mechanics at the Politecnico di Torino as associated professor. He became Full Professor in Biomedical Engineering in 2011. Gianluca Ciardelli is coordinating a group of 15 people on average (Graduate Students and Post-docs, with an interdisciplinary background ranging from chemical, biomedical engineering and chemistry) carrying out research in the development of biomedical polymers and realisation of scaffolds for tissue engineering, drug delivery in nanomedicine, molecular recognition, tissue and organ 3D models. He is currently teaching at bachelor (Chemical Bioengineering), Master (Bionanotechnology), Level at Politecnico di Torino, where is he also Coordinator of the Ph.D course in Bioengineering and Surgical Medical Sciences.
He has an h-index is 38 with around 5000 citations.

Jasmine Coles-Black

3D printing in procedural simulation - cheap as chips?

 

bio

Dr Jasamine Coles-Black is a Vascular Research Fellow at Austin Health, where she is a founding member of 3D Med Lab. She received her Doctor of Medicine from the University of Melbourne in 2016. Her research interests are in the emerging applications of 3D printing in the medical field. To date, she has published numerous articles on the subject. Jas is on a crusade to upskill fellow clinicians in medical 3D printing, and raises the general public's awareness of the technology via traditional and social media channels.

Simon Cool

Ageing and Cell Therapy

 

bio

Simon Cool received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences until 2003. He then joined the Institute of Molecular and Cell Biology, A*STAR, Singapore as a Principal Investigator and in 2008 moved to the Institute of Medical Biology, A*STAR to further his research in regenerative medicine. Currently, as Senior Principal Investigator of the Glycotherapeutics Group, Prof Cool is focused on developing novel glycosaminoglycan biomolecules that enhance bone and cartilage repair and control adult human mesenchymal stem cell activity. He has 36 granted patents across 14 families in the field of glycosaminoglycan biochemistry, regenerative medicine and stem cell science and more than 130 publications. Prof Cool is an Adjunct Professor (Research) in the Department of Orthopaedic Surgery at the National University of Singapore and is currently an elected executive committee member and Vice-Treasurer of the Singapore Stem Cell Society. He is also Section Editor for the Journal of Molecular Histology, and serves on the Editorial Boards of Biomaterials, the Journal of Tissue Engineering and Regenerative Medicine, and Stem Cells and Development.

Deirdre Coombe

3D silk biomaterial scaffolds, extracellular matrices and skin tissue repair

 

bio

Deirdre Coombe, PhD, BSc Hons (University of Adelaide) is a Professor at Curtin University, Western Australia. She is recognised internationally for her work with the extracellular matrix and with carbohydrate-protein interactions and the therapeutic potential of carbohydrate-based drugs. In recent years her work on the extracellular matrix has focused on its contribution to cell and tissue differentiation, as well as to cancer biology and in particular to melanoma cell migration and invasion. She has worked at the Australian National University; Imperial Cancer Research Fund, London; National Institute for Medical Research, London; Glycobiology Institute and Sir William Dunn School of Pathology both of Oxford University. In 1994 she established her research lab at the Institute for Child Health Research in Perth, before joining Curtin University in 2000. She has had continuous research funding for 25 years raising more than AU$8.5 million in research grants and contracts. She has published over 60 research articles and book chapters, and has edited an eBook. She is an inventor on 6 patent families, which are in the national phase or granted. In 2006 she co-founded Glycan Biosciences Pty Ltd., now Glycan Biosciences LLC in Philadelphia USA. Her experience straddles academia and business. Deirdre has a keen interest in the translation of academic, biomedical research into the clinic.

Justin Cooper-White

 

bio

Caroline Curtin

 

bio

Caroline Curtin obtained her BSc in Biomedical Science from the National University of Ireland, Galway (NUIG) in 2004 followed by her PhD in 2010 from the Regenerative Medicine Institute at NUIG. During this time, she also worked as a Research Assistant for Cellular Arthroplasty for Regeneration in Arthritis (CARA), NUIG in collaboration with an industrial partner, Smith & Nephew, a global leader in medical technology, and the Irish Industrial Development Authority, assessing the potential of adult stem cells as a treatment for arthritis with a strong translational, commercialisation and fast-track product development focus. She was recruited as a post-doctoral researcher to the Tissue Engineering Research Group (TERG) in the Royal College of Surgeons in Ireland (RCSI) in 2010 assessing smart scaffolds for bone tissue regeneration under the supervision of Professor Fergal O’Brien. Dr. Curtin is currently employed as a Lecturer in Anatomy and Principal Investigator in the TERG. She is co-supervisor of 3 PhD students, with 1 PhD graduated, has supervised numerous MSc and undergraduate students and has authored > 17 research articles in leading international journals. She is an ad-hoc reviewer for >15 international journals, has presented at > 40 international conferences, and been an invited speaker and chair at a number of conferences. Her research focuses on development of gene-activated scaffold systems for tissue engineering with a particular focus on bone and cartilage, and utilising scaffolds as 3D tumour models for development of novel cancer treatments.

Mark Daniell

 

bio

A/Prof Daniell is a senior consultant Ophthalmic Surgeon with a distinguished career in ophthalmic practice. He is head of the corneal service at the Royal Victorian Eye and Ear Hospital (RVEEH), overseeing a team of surgeons performing corneal transplantation. He is Founding Chair of the ANZ Corneal Society and Medical Director of the Lions Eye Bank. Previously he was Head of Ophthalmology at the Royal Melbourne Hospital.
A/Prof Daniell is also a notable ophthalmic researcher with a significant interest in a bioengineered cornea, developing the concepts and being the driving force for this project. He is head of Surgical Research at the Centre for Eye Research Australia. He is the founder of the Keratoconus International Consortium and is a Honorary Professor at Harbin University in China.
In addition to his medical practice and research, A/Prof Daniell volunteers a great deal of his time to supporting the ophthalmic profession through roles on boards and committees. He has been a Section Editor and Board Member of the Clinical Experimental Ophthalmology Journal and reviews for most major ophthalmology journals. He was Chairman of the Ophthalmic Research Institute of Australia (ORIA) for six years and continues to review grants for National Health and Medical Research Council and ORIA. He is involved in teaching ophthalmology to students, registrars and fellows. He has been an examiner for ophthalmology for over 10 years and supervises several post graduate students. He has served on the RANZCO Board for 10 years and is currently President of RANZCO.

Claudia Di Bella

 

bio

Dr Claudia Di Bella is an academic orthopaedic surgeon highly specialised in musculoskeletal oncology, advanced robotic assisted surgery and 3D printing.
Dr Di Bella is the leader of the Cartilage Regeneration Program of Research at the University of Melbourne (Australia), centred over the use of advanced 3D printing technologies, including surgical 3D bioprinting, robotics and stem cells for the regeneration of the musculoskeletal system. Dr Di Bella has recently received the prestigious Royal Australasian College of Surgeons Senior Lecturer Fellowship and won the Australian and New Zealand Orthopaedic Research Society (ANZORS) Early Career Award. Dr Di Bella has led her team to successfully secure more than 15 national peer reviewed grants, reinforced and strengthened national and international collaboration with key players in the field, and strongly contributed to the advances of the Biofab3D, the first Australian biofabrication hub embedded in the hospital setting. The successes of Dr Di Bella’s team have been recently recognised internationally (winner of the Orthoregeneration Award for the most innovative work in orthoregeneration) and nationally (Finalist at the prestigious NSW Eureka prize for Excellence in Interdisciplinary Scientific Research), and showcased by national media such as ABC news and National Geographic.
Dr Di Bella is very passionate about gender equality in STEM-M, and for this reason she is a mentor in the academic surgery program of the University of Melbourne as well as a mentor for women in medicine at St Vincent’s Hospital.

Yanan Du

 

bio

Dr. Yanan Du received his B.Eng. degree in Chemical Engineering from Tsinghua University and Ph.D. in Bioengineering from National University of Singapore. Dr. Du completed his postdoctoral training at Harvard-MIT Division of Health Science and Technology, MIT and Brigham &Women's hospital, Harvard Medical School. In 2010, he joined the faculty at Department of Biomedical Engineering, School of Medicine, Tsinghua University as principal investigator and obtained tenure in 2016. Dr. Du’s research focuses on developing Micro-engineered Cell-based Assays and Therapy Platform for drug screening, disease study and regenerative therapy. Dr. Du has published ~70 high-impact papers in journals including Nature Materials, PNAS, Advanced Materials, Biotechnology Advances, Biomaterials, Advanced Functional Materials, Lab on Chip etc. Meanwhile, He has also published eight book chapters and obtained the grant of 10 patents.

Yujiang Fan

 

bio

Professor Yujiang Fan received his PhD degree in Materials Engineering Research from the University of Tsukuba in 2001 and worked in Kyushu Institute of Technology and National Institute for Materials Science at Japan. He was then appointed as a professor in Sichuan University in 2006. He is currently Vice Dean of National Engineering Research Center for Biomaterials in Sichuan University, and over fifteen social appointments, including the Board Member of Chinese Society for Biomaterials. Prof. Fan has developed new biomaterials such as hydrogel biomaterials that can induce cartilage formation in clinical research, bone-inducing materials that can be used for load-bearing site repair, and "smart" drug carrier materials. guHis research has received strong support from both international and domestic level. As a project leader, he has been granted over 13 research projects with a total funding of 7 Million USD. To date, he has published more than 90 SCI papers, over 60 invited lectures at international and domestic academic conferences, applied for more than 50 Chinese invention patents and 3 Japanese patents.

John Forsythe

Microfluidic Encapsulation of MSCs in Gelatin Microspheres for Bottom Up Assembly of Cartilage Tissue

 

bio

Prof Forsythe is an academic in the Department of Materials Science and Engineering at Monash University and has research interests in biomaterials, bioengineering and hydrogels.

Benjamin Fournier

Gingival fibroblast: A kind of neural crest stem cells

 

bio

Dr. Benjamin Fournier is an Associate Professor at the Biological Sciences Paris Diderot University, Dental Faculty Garancière. His group focuses on oral healing. Their favourite model is the oral mucosa ad integrum healing model with the associated fibroblasts and stem cells. They also explored the embryo lineages of oral structures. In parallel with lineages cartography, they study the specificities of their transcriptomes and proteomes. By determining these, they hope to better understand oral rare diseases.

Jess Frith

 

bio

Jess completed her PhD at the University of York, UK before postdoctoral training with the Cooper-White group at the Australian Institute of Bioengineering and Nanotechnology, Brisbane. In 2013, she was awarded a prestigious Australian Research Council DECRA fellowship and in 2017 received a Young Tall Poppy Science Award from the Australian Institute of Policy and Science. Jess is currently a Senior Lecturer in the Department of Materials Science and Engineering at Monash University. Her research lies at the interface of cell biology and engineering, using biomaterials to develop an understanding of cellular mechanotransduction and applying these findings to promote tissue regeneration.

Jun Fu

 

bio

Professor Jun Fu received his BSc from Wuhan University in 1999, and PhD degree from Changchun Institute of Applied Chemistry Chinese Academy of Sciences (CAS) in 2005. He worked as a visiting scholar at the Max Planck Institute for Polymer Research from 2005 to 2007, and as a Research Fellow in Massachusetts General Hospital, Harvard Medical School. In 2010, he was appointed as a full professor in Ningbo Institute of Materials Technology and Engineering, CAS. His research focuses on tough and functional hydrogels, particularly covering applications in biomedical research, tissue engineering, flexible sensors, wearable devices, and soft actuators and manipulators. Prof. Fu has coauthored more than 100 peer-reviewed journal papers, book chapters, and monographs receiving more than 3500 citations and H index of 30. He serves as an Advisory Board member for Journal of Materials Chemistry B, and member of Materials Research Society, Chinese Materials Research Society, Chinese Biomaterials Research Society, and Chinese Chemical Society.

Tsutomu Furuzono

 

bio

He received his Ph.D. of Engineering from Kagoshima University, Kagoshima, Japan in 1996 (Prof. M. Akashi). Following his research life as a postdoctoral fellow in University of Washington, Seattle, WA, USA (Prof. A.S. Hoffman’s Lab., 1996-1997), National Institute of Sericultural Entomological Science, Tsukuba, Ibaraki, Japan (Dr. Y. Tamada’s Lab., 1997-1999), National Institute for Research in Inorganic Materials, Tsukuba, Ibaraki, Japan (Dr. J. Tanaka’s Lab. 1999-2000). He took up the Division Head for Department of Biomedical Engineering, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan (2000-2010). He is currently Professor for Department of Biomedical Engineering, School of Biology-Oriented Science and Technology, Kinki University from 2010. He had been the Department Chair (2011-2018) and Vice Dean (2016-2018). He received also Ph.D. of Med. Sci. from Osaka University, Osaka, Japan in 2016 (Prof. Y. Sawa, Cardiovascular Surgery). His research activities are in the fields of material science concerning polymer and ceramics for medical devices, artificial organs and regenerative medicine. Basically, his research aims for increasing of QOL and ADL of chronic kidney disease (CKD) patients, because he is living over 32 years by all renal replacement therapy such as center hemodialysis, peritoneal dialysis, home-hemodialysis and kidney implantation from donor brain death.

Kathryn Futrega

 

bio

Dr Kathryn Futrega received her PhD in Biomedical Sciences from the Queensland University of Technology, Brisbane, Australia in 2016. During this time, she worked on umbilical cord blood expansion and cell delivery methods, as well as cartilage tissue engineering. She developed a custom cell culture device for growing large numbers of microtissues, called the Microwell-mesh. This device allows for the long-term culture of hundreds-to-thousands of microtissues over long durations in a well plate, without microtissue displacement. This culture device has been particularly useful in the in vitro production and comparison of cartilage-like microtissues derived from bone marrow stromal cells (BMSC) and articular chondrocytes from healthy cartilage tissues. Dr Futrega is currently training as a post-doctoral fellow at the National Institutes of Health, USA. Prior to this, she completed a Bachelor of Science in Biochemistry with a specialisation in Biotechnology from the University of Waterloo, Canada. Her current research interests include cartilage tissue engineering, understanding joint development, bone and bone marrow biology, and the development of strategies to maximise the therapeutic potential of stem and progenitor cells through ex vivo manipulation.

Xing Gao

Multiple mouse models for the investigation of tumor biology function in NF2-related vestibular schwannoma

 

bio

2007-2011 Resident, Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, China
2011-2012 Chief Resident, Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, China
2012-2013 Medical student, Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
2014-Recent Attending, Dept. Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, China

Ananta Ghosh

Silk sericin based hydrogel and nanofibrous matrices for skin regeneration

 

bio

Born in January 1957 in India, Ananta K. Ghosh has completed his B.Sc in 1976, M.Sc. in Physiology in 1978 and Ph.D. in Biochemistry in 1987 from the University of Calcutta. Next he moved to USA, and completed his postdoctoral studies from the University of Southern California, Harvard Medical School and Stanford University School of Medicine from 1985 to 1993). He then joined as Assistant Professor of Research Pathology in the University of Southern California (1993-1995) and then moved to India in 1995 to join as Assistant Professor in the Indian Institute of Technology Kharagpur. Currently, he is a Professor in the Department of Biotechnology, Indian institute of Technology Kharagpur, India. He also worked as a visiting professor/scientist in the University of Washington, Seattle, USA, visited Vienna and university of LEEDS, UK
Dr. Ghosh has been working on microbial (parasite and viral) diseases of human and other animals. During his graduate research he has developed hamster model for Indian visceral leishmaniasis for studying the pathogenesis and efficacy of various drugs against this disease. During his post-doctoral research he has worked on gene regulation / genetic variation and receptor characterization of FeLV, and HIV. Currently he is working on a cypovirus (a dsRNA virus) and microsporidia infecting tasar silkworm, Antheraea mylitta to understand disease pathogenesis as well as purification and characterization antimicrobial peptides from insects. His research is currently focusing on tissue engineering using silk protein sericin and fibroin as biomaterials. He has published 88 papers in various Journals.

Shaoqin Sarah Gong

 

bio

Dr. Shaoqin Sarah Gong is a Vilas Distinguished Achievement Professor in the Department of Biomedical Engineering and the Wisconsin Institutes for Discovery at the University of Wisconsin–Madison. She received her BA and MS degrees from Tsinghua University and her PhD degree from the University of Michigan–Ann Arbor—all in Materials Science and Engineering. Prof. Gong is a fellow of the American Institute for Medical and Biological Engineering. She has co-authored over 160 peer-reviewed journal articles with an H-index of 56. She is an editorial board member for several journals including Biomaterials, Theranostics, Biofabrication, and Nanotheranostics. She has also served as an Associate Editor for Biomaterials and is a winner of a number of awards including the NSF CAREER Award and NIH Career Development Award. Prof. Gong’s current research focuses on the development of biomaterials and nanomedicines for various applications. Her research group has developed a series of multifunctional drug/agent nanocarriers including unimolecular micelles, polymer nanocages, polymer vesicles, and polymer-functionalized inorganic nanoparticles for targeted therapy, as well as genome editing, to treat and monitor various major health threats including cancers and vascular disorders, as well as eye and brain diseases.

Stan Gronthos

Epigenetic Regulation of Skeletal Stem Cell Growth, Senescence and Cell Fate Determination

 

bio

Stan Gronthos is Professor of Stem Cell Biology and Regenerative Medicine, and Founder and Head of the Mesenchymal Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide. He is a Senior Principal Research Fellow of the South Australian Health and Medical Research Institute and a Fellow of the American Society of Bone and Mineral Research. He has co-authored over 206 publications (>38,000 citations) and 13 patents describing the composition of matter and application of purified postnatal human mesenchymal stem cells derived from bone marrow, adipose tissue, and dental tissue. His stem cell patent family was the foundation intellectual property for the formation of Mesoblast Ltd., one of the worlds largest regenerative medicine based companies, which is currently sponsoring multiple human Phase II/III trials in cardiovascular disease, diabetes, osteoarthritis, cancer and immune/inflammatory conditions.

Stan Gronthos

Epigenetic Regulation of Skeletal Stem Cell Growth, Senescence and Cell Fate Determination

 

bio

Stan Gronthos is Professor of Stem Cell Biology and Regenerative Medicine, and Founder and Head of the Mesenchymal Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide. He is a Senior Principal Research Fellow of the South Australian Health and Medical Research Institute and a Fellow of the American Society of Bone and Mineral Research. He has co-authored over 206 publications (>38,000 citations) and 13 patents describing the composition of matter and application of purified postnatal human mesenchymal stem cells derived from bone marrow, adipose tissue, and dental tissue. His stem cell patent family was the foundation intellectual property for the formation of Mesoblast Ltd., one of the worlds largest regenerative medicine based companies, which is currently sponsoring multiple human Phase II/III trials in cardiovascular disease, diabetes, osteoarthritis, cancer and immune/inflammatory conditions.

Qi Gu

Novel Bioinks for Stem Cells and Vascular Tissue Engineering

 

bio

Principal Investigator for the group of Intelligent Biomaterials and Biomedical Engineering, Institute of Zoology, Chinese Academy of Sciences.
Dr. Gu has an interdisciplinary training in materials chemistry and stem cells. Gu laboratory focuses on the developing novel biomaterials and advanced technologies including 3D/4D bioprinting to regulate stem cell fate and to fabricate functional 3D organs and even live organisms in vitro and applying them to understanding the mechanism of life and establish novel therapeutic methods.
During his first doctoral career, Dr. Gu has investigated the pluripotent state of humans, primates and other animal species towards identifying definitive ways for regulating, characterising and purifying human pluripotent stem cells. Drawing from his studies in Beijing, he completed a second PhD at University of Wollongong where he has developed novel biomaterials and used bioprinting for advanced human stem cell culture, differentiation and 3D tissue engineering, which is overcoming the limitations of conventional 2D culture methods, enabling better control of stem cell survival, fate and tissue organisation for more effective cell and tissue modelling in vitro.

Karan Gulati

 

bio

Dr. Karan Gulati is working as a NHMRC Early Career Fellow (Jan 2018-Dec 2021) at the School of Dentistry, The University of Queensland, QLD. His main research focus is ‘nano-engineered therapeutic titanium dental implants towards enhanced soft- and hard-tissue integration’. Prior to current appointment, Dr. Gulati worked at the School of Dentistry and Oral Health, Griffith University, Gold Coast, QLD as a Research Fellow (2016-17), working in the area of nano-engineered dental implants. He completed PhD in the domain of 'Nano-Engineered Bone Implants' from School of Chemical Engineering, The University of Adelaide, SA in 2015, and was awarded Dean’s Commendation for Doctoral Thesis Excellence. Dr. Gulati has over 8 years of research experience working with nano-engineered titanium implants, nanotubes/nanopores, local drug delivery, bone/dental implants, and therapeutic/bioactive titanium surfaces. To-date Dr. Gulati has published over 32 peer-reviewed journal articles (h-index 15), 8 peer-reviewed conference publications, and have presented over 53 times in national/international conferences (21 oral presentations, including 7 invited talks). Furthermore, Dr. Gulati has attracted over 482,000 $ in research funding (since 2016) and over 6000 $ in travel grants (since 2013). In 2018, research funding awarded to Dr. Gulati exceeded 106,337 $ (all four grants as chief investigator).

Tianying Guo

 

bio

Dr. Guo is a full professor in Key Laboratory of Functional Polymer Materials, Ministry of Education, College of Chemistry, Nankai University, China. His research interests are mainly focused on the development of functional polymeric materials via controlled/living polymerization and click chemistry, and their applications in non-viral gene therapy and molecular imprinting etc. Recently, his research group developed a novel metal coordination strategy to construct highly efficient and safe non-viral gene delivery vectors, which opens up a new avenue for the conversion of commercially avialable low-cost polycations, such as polyethylene imine and poly(L-lysine), to clinically viable gene delivery vectors, especially for the hard-to-transfect primary cells and stem cells. Prof. Guo has published multiple high impact research papers in peer-reviewed scientific journals such as Journal of the American Chemical Society, Biomaterials, ACS Applied Materials & Interfaces, Journal of Controlled Release, Chemical Communications and ACS Macro Letters etc. He has presented his research findings at multiple national and international conferences.

Dr. PingPing Han

Extracellular vesicles (EV) as diagnostic biomarkers for diseases

 

bio

Dr Pingping Han is a UQ Development Fellow within the School of Dentistry, Faculty of Health and Behavioural Sciences, The University of Queensland. Dr Han graduated from the Queensland University of Technology in Biomedical Engineering. Her research led to more than 19 publications in the leading journals in the field of Material Science, Engineering and Medicine (e.g. Journal of Bone and Mineral Research, Biomaterials, Biomaterials Sciences, ACS Applied Materials & Interfaces). Dr Han’s expertise lies in the molecular mechanism investigations, epigenetics modulation in oral and bone diseases, and her current project is focusing on utilising extracellular vesicles as a potential diagnostic biomarker for the periodontitis-a prevalent inflammatory disease.

Pingping Han

Salivary small extracellular vesicles as diagnostics for periodontal disease

 

bio

Xiaojuan Hao

 

bio

Dr Xiaojuan Hao is a Senior Research Scientist and Project Leader in the Biomedical Manufacturing Program within the CSIRO Manufacturing business unit. Dr Hao joined CSIRO in 2006 after working in Melbourne University and the University of New South Wales as a postdoc. She was a Team Leader of RAFT Bio-application Team and led a team to successfully deliver a number of significant projects. Her research areas include RAFT polymerisation to prepare various macromolecular structures, polymer modification of nanomaterials such as gold nanoparticles and carbon materials (fullerenes, CNTs and GO), biomaterials for drug delivery and medical devices, and imaging contrast agents, etc. She was awarded a CSIRO Medal for Research Achievement in recognition of her contributions to novel vision correction polymer technologies. She was also awarded a CSIRO Office of the Chief Executive (OCE) Julius Award in recognition of her scientific achievements.

Damien Harkin

 

bio

Damien Harkin is a Professor in the School of Biomedical Sciences at the Queensland University of Technology (QUT) and is Director of Ocular Cell Therapies at the Queensland Eye Institute (QEI). At QUT, Dr Harkin teaches techniques for the preservation and staining of tissue samples, acquired for the purpose of diagnosing disease. As a research scientist, Damien has published extensively on the use of stem cells and biomaterials for the treatment of eye disease and is currently developing improved therapies for the management of age-related macular degeneration.

Daniel Heath

Cell secreted matrices - superior cell culture substrates for MSCs

 

bio

Daniel is a Lecturer at the University of Melbourne where he leads a group focused on development of next generation biomaterials. His group has particular foci on cardiovascular materials and cell secreted matrices.

Akon Higuchi

 

bio

Dr Badrul Hisham Yahaya

 

bio

Assoc. Prof Dr. Badrul Hisham Bin Yahaya (Ph.D.), currently is the Director of Animal Research and Service Centre (ARASC) of Universiti Sains Malaysia, a Principal Investigator and the former Head of Regenerative Medicine Cluster, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia. Dr Badrul obtained his BSc (with Hons) degree in Genetics from the Universiti Kebangsaan Malaysia (2002), MSc in Human Genetics from the Universiti Sains Malaysia (2006). Dr. Badrul was awarded a fellowship of Academic Staff Training Scheme (ASTS) from the Universiti Sains Malaysia and the Malaysian Government to pursue his MSc and Ph.D. degrees. For his PhD, Dr. Badrul received his training at the Roslin Institute and Royal (Dick) School of Veterinary Studies, the University of Edinburgh, Scotland. In professional bodies, Dr. Badrul is an active member in various national and international societies. Dr. Badrul received numerous invitation from local and international bodies to share his current findings in stem cell therapy and cancer stem cell research in various scientific meetings. Currently he is the Tissue Engineering and Regenerative Medicine Society of Malaysia (TESMA) Board Member (2017 – 2019) where he was the vice president of TESMA (2015-2017), and former Board Member of Malaysian Society for Stem Cell Research and Therapy (MSCRT). Dr Badrul is a Visiting Professor at Xinxiang Medical University (XXMU) Henan Province, China and Fellow Academic of Kolej Burhanuddin Helmi, Universiti Kebangsaan Malaysia (UKM), Bangi. Dr Badrul is an Editor-in-Chief of the Journal of Biomedical and Clinical Sciences (JBCS) published by AMDI USM. Dr Badrul is also an Editorial Board Members, Biomedical Research and Therapy journal, the official journal of Stem Cell Institute, University of Science, VNUHCM, Ho Chi Minh City, Vietnam (the journal is indexed in Web of Science and Scopus).

Megan Ho Yi-Ping

Microfluidics enabled protein delivery into red blood cells (tentative title)

 

bio

Dr. Ho Yi- Ping, Megan received her B.S. and M.S. in Power Mechanical Engineering from National Tsing-Hua University, Taiwan. Dr. Ho received her Ph.D. degree in Mechanical Engineering from Johns Hopkins University in 2008. She did 3 years of postdoctoral training with Duke University. She worked as assistant professor in the Department of Molecular Biology and Genetics in Aarhus University, Denmark from 2012, where she co-founded a start-up company, Zymonostics, situated in Demark. Megan join the Chinese University of Hong Kong in 2016, and now she is an Assistant Professor at Department of Kong, and her research focuses on integrating nanophotonics, novel molecular constructs and microfluidics for detecting nucleic acids in the context of disease diagnostics and gene therapy. She has received 15 academic honors and awards, published 39 peer-reviewed journal articles, 61 peer-reviewed proceedings and conference abstracts, 2 granted patents and 4 invention disclosures. The results that she presented have been recognized internationally and received prestigious awards from American Society of Gene Therapy and Controlled Release Society.

Takashi Hoshiba

 

bio

Yu-Chen (Andy) Hu

Innovative technology for genetic engineering in regenerative medicine

 

bio

Dr. Yu-Chen Hu’s research interests include vaccine development, gene therapy, tissue engineering, cancer therapy and synthetic biology. Dr. Hu's lab has developed the enterovirus 71 (EV71) vaccine based on virus-like particle technology and also paves a new avenue to the use of baculovirus as a novel vector for regenerative medicine and cancer therapy. Dr. Hu has also employed burgeoning CRISPR technology and synthetic biology for the metabolic engineering of microorganisms and stem cells for production of bio-derived chemicals and tissue regeneration. In particular, he has recently developed various CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) and CRISPRai platforms to modulate stem cell differentiation so as to improve regeneration of bones and nerves.
Dr. Hu has won the Asia Research Award, Outstanding Research Award (Ministry of Science and Technology, 2006, 2014), BEST Biochemical Engineering Achievement Award, Wu Ta-You Memorial Award, Outstanding Academia-Industry Research Award and Outstanding Young Investigator Award in Taiwan. He is a fellow of American Institute for Medical and Biological Engineering (AIMBE), Program Chair of the Tissue Engineering International & Regenerative Medicine Society-Asia Pacific (TERMIS-AP) 2016 meeting, Conference Chair of Asian Congress of Biotechnology (ACB meeting 2019) and the Vice President of Biotechnology and Biochemical Engineering Society of Taiwan. He currently serves as the associated editor of Current Gene Therapy, deputy editor of Journal of Taiwan Institute of Chemical Engineers, and Coordinator of Chemical Engineering Division, Ministry of Science and Technology.

Lynn Huang

Extracellular matrices for skin regeneration and keloid therapy

 

bio

Dr. Lynn L.H. Huang is a Distinguished Professor in the Department of Biotechnology & Bioindustry Sciences and Institute of Clinical Medicine at the National Cheng Kung University in Taiwan. Since 2008, she was elected as a fellow of Biomaterials Science and Engineering (FBSE) because of her significant contributions in research and education. Except numerous research awards and innovation awards, she was awarded Lifetime Achievement Inventor in 2014. She served as a Taiwan delegate in the International Union of Societies for Biomaterials and Engineering for 18 years. She is now an editorial honorary advisory board member for the "Journal of Biomaterials and Tissue Engineering".

She has been working in the fields of extracellular matrix biochemistry and biomaterials for over 35 years and was the first person proposed a non-contractible collagen-hyaluronan matrix in the world. Her expertise is in biochemistry of collagen and hyaluronan, biomaterials, tissue engineering, cell biology, 3-dimensional culture, biocompatibility, animal wound healing models, etc. Her lab has successfully established a series of novel non-contractible porous collagen-glycosaminoglycan scaffolds and the plasticity of mesenchymal stem cells by extracellular microenvironment. Recently, with a strict non-regenerative hind limb ischemia model in diabetic mice, she has invented certain novel drugs for the ischemic treatment to prevent limb amputation. In recent 5 years, 60 international patents invented by her were approved and 24 peer-reviewed scientific papers were published.

Nathaniel Hwang

 

bio

Nathaniel S. Hwang is currently an Associate Professor in the School of Chemical and Biological Engineering at Seoul National University, Republic of Korea. Prof. Hwang is a member of Institute for Chemical Processes and BioMAX Institute at Seoul National University. In addition, he also holds an adjunct position in Stem Cell Graduate Program and Interdisciplinary Program in Bioengineering at the Seoul National University.
Prof. Hwang received a bachelor degree in Biomedical Engineering from Johns Hopkins University Whiting School of Engineering in 2002. He obtained his Ph.D. in Biomedical Engineering from the Johns Hopkins School of Medicine in 2007 under the guidance of Professor Jennifer Elisseeff. After doctoral studies, he was a visiting scholar at the University of California, San Diego, Department of Bioengineering, and worked with Professor Shyni Varghese. From 2008 through 2011, he worked as a postdoctoral associate in Professor Robert Langer’s laboratory at Massachusetts Institute of Technology. In 2011, Dr. Hwang joined the School of Chemical and Biological Engineering at Seoul National University.
Prof. Hwang is currently leading a group of students that work together to develop new biomaterials, study stem cells, and design new technologies for regenerative medicine. In particular, Prof. Hwang’s laboratory is working toward the fabrication of bio-synthetic microenvironments conducive to stem cell differentiation by manipulating scaffold properties and incorporating the desired biological signals. In addition, Prof. Hwang’s laboratory is developing non-viral strategies for a direct conversion stem cell technology. He has published over 95 research articles and book chapters covering biomaterials and stem cells for musculoskeletal tissue regeneration (h-index >34, citations>4486). Prof. Hwang is an active member of Tissue Engineering and Regenerative Medicine International Society. In 2013 TERMIS-AP Shanghai Meeting, he organized a biomaterials symposium. In 2014 TERMIS-AP Daegu Meeting, he served as a member for the Organizing Committee for the Student and Young Investigator Section (SYIS) and SYIS symposiums. In addition to TERMIS, Prof. Hwang is involved in the Korean Society for Biomaterials as Scientific Program Committee member.

Saso Ivanovski

 

bio

Professor Saso Ivanovski graduated with BDSc (Honours) from the University of Queensland Dental School in 1993. He subsequently completed a BDentSt research degree in 1995, following which he was awarded a National Health and Medical Research (NH&MRC) postgraduate scholarship and commenced a PhD which was completed in 2000. This was followed by specialist training leading to the award of an MDSc in Periodontology in 2002. During his studies, Prof. Ivanovski worked in private practice, initially as a dentist (1994-2002), and subsequently as a specialist periodontist. Prof. Ivanovski is a fellow of the ITI, a member of the Dental Board of Queensland, the past federal president of the Australasian Osseointegration Society (AOS), and current federal president of the Australian Society of Periodontology (ASP). Prof. Ivanovski has published over 70 articles in the peer-reviewed international literature, has lectured extensively nationally and internationally and has been the recipient of numerous research grants and awards. He leads an internationally recognised research group with an interest in clinical implantology and periodontology, as well as the cellular and molecular aspects of osseointegration and periodontal regeneration.

Kanika Jain

Buccal Fat Pad: An untapped stem cell source for regenerating the oral and dental periodontal tissues

 

bio

Dr. Kanika Jain is a trained stem cell biologist with almost a decade of experience of working in research (Masters AND PhD) of which 6 years has been dedicated to the study of pluripotent and adult stem cells. She obtained her doctoral degree from Monash University in May 2016 and has previously worked as a post doc within The Ritchie Centre at Hudson Institute of Medical Research, Melbourne. She is currently working within the UQ School of Dentistry and her research aims to understand the mechanisms of periodontal tissue repair and regeneration using mesenchymal stromal/stem cells and scaffolds.

Jaganmohan Jangamreddy

Biomaterials mimicking tumour microenvironment for retinoblastoma organoid cultures

 

bio

Xinquan Jiang

 

bio

Professor Jiang is now served as dean of faculty of dentistry, vice dean of college of stomatology, Shanghai JiaoTong University, director of the department of prosthodontics and oral bioengineering/regenerative medicine lab of Shanghai Ninth People’s Hospital, deputy director of Shanghai Key Laboratory of Oral Medicine, director of Shanghai Engineering and Research Center in Universities for Advanced Dental Technology and Materials, the Deputy Academic Director of National Clinical Research Center for Oral Disease. Currently, he is also an honorary professor in the University of Sydney, Australia. He serves as councilor of International College of Prosthodontists (ICP) and fellow of International College of Dentists (ICD), deputy chairman of Tissue Engineering and Regenerative Medicine Branch of Chinese Society of Biomedical Engineering, vice president of Chinese Prosthodontic Society, vice president of Stomatology Scientific Research Management Committees, Councilor of Chinese Society for Biomaterials, President of Dental and Craniofacial Biomaterials and Application Committees of Bone repair Materials and Instruments Branch of Chinese Society for Biomaterials, and Vice President of Standing Committees of Tissue Engineering and Regenerative Medicine Branch of Chinese Society of Biomedical Engineering. Jiang was also invited as editorial member of 6 International Journals, including Tissue Engineering.
Professor Jiang has been working on regenerative medicine for dental and maxillofacial tissue accredited for decades. Now he has 5 national invention patents. As first or communication author, he has 108 publications in peer-reviewed journals with the total impact factor (IF) of 552. His publications include the native work published in “Tissue Engineering” and “Advanced Materials”, the cover story paper in JDR, and the work selected as “the images of the year” by Biomaterials. And he has been invited by IJP’s major funder Professor Zarb, to present commentary published in the prestigious International Journal of Prosthodontics. Professor Jiang has been invited as keynote speaker at over 20 international conferences including the 10th World Biomaterials Congress. And he, as the executive chairman, has successfully hosted the 1st Young Scientist Forum of stomatology of China association for science and technology, 2011 AAP meetings, and annual Shanghai international prosthodontic symposiums.
He won the prestigious IADR/Unilever Hatton Award from the IADR in 2005 and secured the prestigious distinguished young investigator grant in NSFC, the leader academics of the “Ten-thousand Talent Program” and “Changjiang scholar” title in China and so on.

Yangzi Jiang

 

bio

Stefan Jockenhoevel

 

bio

Jinmyoung Joo

 

bio

Prof. Jinmyoung Joo is an assistant professor of Biomedical Engineering at the Ulsan National Institute of Science and Technology (UNIST), where he also holds an affiliate appointment in Chemical Engineering department. He received B.S. (2007) and Ph.D. (2012) degrees both in Chemical Engineering from POSTECH, and then continued his studies on the functional nanomaterials for biomedical applications as a postdoctoral research associate in the Department of Chemistry and Biochemistry at University of California, San Diego with Prof. Michael J. Sailor. He started his independent career as an Assistant Professor in the Department of Convergence Medicine at the University of Ulsan College of Medicine in 2016, and he joined the faculty in School of Life Sciences at the UNIST in January, 2019. He has been interested in understanding the interaction of nanomaterials with complex biological systems, engineering novel nanostructures that can effectively understand tissue microenvironment and target diseases such as cancer and neurodegenerative diseases. His lab has focuses on leveraging nanoscale materials to study biological findings and to bridge them to translational medical platforms such as bioimaging and drug delivery systems.

Elena Juan Pardo

 

bio

Elena M. De-Juan-Pardo, Ph.D., is a Senior Research Fellow and Deputy Director of the Centre in Regenerative Medicine at the Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT) (Brisbane, Australia). She is as a Materials Engineer with over 14 years of experience in biomaterials and biofabrication for tissue engineering, regenerative medicine and cancer modelling. Her current research focuses on the development of melt electrowriting, a pioneering 3D printing technology that enables the production of highly controlled fibrous scaffolds with tailored mechanical properties for soft tissue engineering. In the past, she established the Tissue Engineering and Biomaterials Group at the Centre of Studies and Technical Research of Gipuzkoa (CEIT, San Sebastian, Spain) and served as Director of the Master in Biomedical Engineering (University of Navarra, Spain).

Naoki Kawazoe

Micro-patterned Surfaces for Regulation of Cell Morphology and Gene Transfection

 

bio

Naoki Kawazoe is currently a Senior Researcher at Tissue Regeneration Materials Group, Research Center for Functional Materials, National Institute for Materials Science (NIMS). He received his Ph.D from Department of Material Chemistry at Kyoto University in March 1999. Then, he became a teaching associate in Department of Biological Science and Technology, The University of Tokushima. In April, 2000, he moved to Nara Institute of Science and Technology (NAIST) as a teaching associate. He then worked as a postdoctoral researcher at National Institute of Advanced Industrial Science and Technology (AIST) and at Toray Industries collaborating with Osaka University. He moved to NIMS in April, 2006 and has been working at Dr. Guoping Chen’s group since then. His current area of interest is nano/micropatterned biomaterials for stem cell manipulation. He has authored more than 120 publications and holds 14 issued patents. He has given more than 30 invited lectures at conferences. He received SRB Excellence Award at the 8th International Conference “Biomaterials, Tissue Engineering & Medical Devices in 2018. He is a delegate of the Japanese Society for Regenerative Medicine (since 2013-) and a councilor of Japanese Society for Biomaterials (since 2018-).

Jin Ke

The role of TLR4 on a CFA injection- or discectomy-induced TMJOA model

 

bio

Expert in temporomandibular joint disease, salivary gland disease, trigeminal neuralgia, cleft lip/palate.

Dr. Ng Kee Woei

Human Hair Keratins as a Nature-Derived Biomaterial

 

bio

Dr. Ng Kee Woei is a mechanical engineer by training, he completed his PhD at the Yong Loo Lin School of Medicine, National University of Singapore, in 2006. Dr Ng underwent postdoctoral training at the Institute of Molecular and Cell Biology and at the Institute of Medical Biology, A*STAR. Now Dr. Ng is Associate Professor of College of Engineering at Nanyang Technological University at Singapore. He has worked on a number of projects to tissue engineer skin, bone and cartilage, including the biology and bioengineering principles of epithelial stem cells, wound healing and keratin dynamics. He is also interested in pursuing fundamental understanding of cell-material interactions, including the toxicological influence of nanomaterials.

Gilson Khang

 

bio

Dr. Gilson Khang was born in 1960 in South Korea, where he obtained his degrees at the Inha Univ (B.S. and M.S.). In 1987, he joined the Dr Hai Bang Lee’s Biomaterials Lab at KRICT (Deajeon, Korea). He was studying for Ph.D. degree at the Department of Biomedical Engineering, The Univ of Iowa (Iowa City, IA, USA) from 1991~1995 under the guidance of Prof Joon B. Park.
His academic career started at the Department of PolymerNano Science and Technology at Chonbuk National University (CBNU) and then tenured by Full Professor in 2009.
From 2006 to 2011, he was the PI of BK-21 (Brain Korea 21 Project) and WCU (World Class University, 3MUD/yr for 5 years) Program at CBNU supported by KMEST. He was Chair Professor in the Department of BIN Fusion Technology of WCU program of CBNU.
Dr. Khang was the one of Founder Members of Asian Tissue Engineering Society (ATES) and one of Founder Members of TERMIS-AP Chapter. Prof. Khang was General Secretary and Treasurer for 2005~2009 of TERMIS-AP Chapter and now served as a council member for TERMIS-AP. Recently, he is TERMIS-AP Past-President, & TERMIS Global President-Elect (2016~2018).
He has co-authored or edited ~30 books. He has published ~600 original research papers, and ~200 editorials, reviews or chapters in books. His papers were cited 15,520 times. (h-index >68) His major scientific contribution has been to appreciate and analyze the importance of natural/synthetic hybrid scaffold to reduce the host inflammation reaction as well as the commercialization for tissue engineered products as cartilage, bone, retinal pigment epithelium, cornea endothelium, etc.
His international collaboration network is really worldwide and tight over 7 countries and 15 Universities. He is engaging the Visiting Professor of Tsinghua Univ, Peking Univ, Zhejiang Univ, China and Wake Forest Institute of Regenerative Medicine, USA.

Kiarash Khosrotehrani

 

bio

Elena M. De-Juan-Pardo, Ph.D., is a Senior Research Fellow and Deputy Director of the Centre in Regenerative Medicine at the Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT) (Brisbane, Australia). She is as a Materials Engineer with over 14 years of experience in biomaterials and biofabrication for tissue engineering, regenerative medicine and cancer modelling. Her current research focuses on the development of melt electrowriting, a pioneering 3D printing technology that enables the production of highly controlled fibrous scaffolds with tailored mechanical properties for soft tissue engineering. In the past, she established the Tissue Engineering and Biomaterials Group at the Centre of Studies and Technical Research of Gipuzkoa (CEIT, San Sebastian, Spain) and served as Director of the Master in Biomedical Engineering (University of Navarra, Spain).

Dokyoung Kim

 

bio

Dokyoung Kim is Professor at the Kyung Hee University, College of Medicine, Republic of Korea. He received his PhD under the direction of Prof. Kyo Han Ahn at POSTECH (2014). He then performed post-doctoral studies at University of California, San Diego (UCSD) under the direction of Michal J. Sailor. He joined the faculty of Kyung Hee University, College of Medicine in 2017, and he currently holds Affiliate Appointments in the Kyung Hee University Center for Converging Humanities, Biomedical Science Institute, and Department of Biomedical Science. He is the author of more than 60 research publications, one book, and 15 patents

Masahiro Kino-oka

Recent progress of cell production based on cell manufacturability

 

bio

Masa (Masahiro KINO-OKA) is one of leaders in the field of manufacturing for cell and tissue products; individuals who seem able to contribute to the standardization of the cell processing facility and bioreactor. His current research interests are “Bioprocess engineering” to establish the cell and tissue manufacturing system including the fields of “Bioreaction Engineering”, “Bioprocess design”, and “Stem Cell Engineering”.
Toward, the current professional status, Masahiro KINO-OKA earned his B.S. in Department of Chemical Engineering at Osaka University in 1989, and M.S. in 1991. He became the research assistant, Department of Chemical Engineering, Osaka University (1991-2000), having the project of bioreactor and process design for plant tissue culture. After getting the Ph.D. in 1996, he spent one year as a visiting staff in the Department of Chemical Engineering, National Institute of Switzerland (ETH) in Zurich and started the new project for bioreactor design for human cells toward clinical application.
After returning Japan (1997), he promoted twice in his five-year tenure (Assistant Professor, Department of Chemical Engineering, Osaka University (2000), Associate Professor, Department of Chemical Engineering, Osaka University (2003), and finally three years ago (2009) he earned a current position of Professor in Biotechnology, Osaka University.
Prior to Department of Biotechnology, Kino-oka had many experiences for bioreactor and process designs for human cell culture toward clinical application. Now he starts new projects for manufacturing including facility design of cell and tissue processing (Development of cell manufacturing and processing system for industrialization of regenerative medicine by Japan Agency for Medical Research and Development(AMED) (2014.4-2019.3)) for development of guidance for cell and tissue processing (good cell and tissue practice, GCTP). To develop the facility, he has joined to ISO to be international member in ISO TC198 / WG9 for aseptic processing as well as ISO TC276 / WG4 for bioprocessing. In addition, he becomes board of directors of the Japanese Society for Regenerative Medicine (JSRM) and Health Science Council member in Minister of Health Labor and Welfare (MHLW), collaborating with regulatory site of Japanese FDA (PMDA) to establish guideline for aseptic cell processing.

Daniel Kolarich

Protein Glycosylation - an overlooked feature impacting Stem Cell Factor and Stem Cell Factor Receptor function

 

bio

Daniel became fascinated with glycobiology and mass spectrometry during his undergraduate studies in Vienna. During his PhD with Professor Friedrich Altmann and his post-doctoral work with Professor Nicolle H. Packer at Macquarie University in Sydney, Australia, he worked intensively on glycopeptide oriented glycoproteomics of human glycoproteins and plant/insect glycoprotein allergens. In late 2010 he took up the opportunity to establish his independent research group at Prof. Peter H. Seeberger’s Department of Biomolecular Systems at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany. There his research was focusing on glycomics and glycoproteomics techniques to investigate the role glycosylation plays in health and disease. He was awarded an ARC future fellowship in late 2016 and joined the Institute for Glycomics at Griffith University in January 2017 continuing his research in disease and evolutionary glycomics and glycoproteomics.

Tushar Kumeria

 

bio

Dr. Tushar Kumeria is an Australian National Health and Medical Research Council (NHMRC) Early Career Fellow at the School of Pharmacy, The University of Queensland (UQ), Australia. He has co-authored 54 high impact journal publications in various internationally renowned journals in the field of nanomaterials, biomaterials, sensing, and drug delivery. He completed my Ph.D. in 2015 from the University of Adelaide with a Doctoral Thesis Medal and Dean’s Commendation Letter. In 2015, he moved to the USA and spent two years at University of California-San Diego (UCSD) as a postdoc with Prof. M. J. Sailor’s group. His research expertise lies in nanoporous materials and their composite for applications in photonics, sensing, and drug delivery. His current research focus is on:
1. Porous silicon based delivery systems for highly efficient and targeted delivery of protein/biologics via oral or other administration route.
2. Porous silicon/Polymer composite and porous titanium dioxide based scaffolds/implants that enable local release of therapeutics and growth factors for accelerated bone regeneration,
3. Porous silicon or porous alumina photonic crystals based point-of-care sensors for diagnostics and environmental applications.

Bin Li

 

bio

Professor Bin Li received the bachelor degree in Polymeric Materials Science and Chemical Engineering from the Department of Chemical Engineering of Tsinghua University in 1996. He received the PhD degree in Materials Science from Tsinghua University in 2001. He then worked as a Research Associate at the Institute of Materials Research and Engineering, Singapore from 2001 to 2004. After that he pursued postdoctoral training at the Department of Orthopaedics, University of Pittsburgh School of Medicine in USA from 2005 to 2009. He also completed two short-term trainings as a visiting research scientist at Carnegie Mellon University in 2004 and Harvard University in 2009, respectively. He joined Soochow University in 2009 as a Specially Appointed Professor and director of the Biomaterials and Cell Mechanics Laboratory (BCML) of Orthopedic Institute. He is the recipient of a number of awards such as the Suzhou Science & Technology Development Award, Orthopaedics Research Award (1st class) from Chinese Orthopaedic Association, Xu Guangqi Program from the French Embassy in China, and France Talent Innovation from the Consulate General of France in Shanghai. He currently serves as the chair of China Development Committee of the International Chinese Musculoskeletal Research Society (ICMRS). He is a fellow of Chinese Orthopaedic Research Society (CORS), Chinese Association of Orthopaedic Surgeons (CAOS), Chinese Association of Rehabilitation Medicine (CARM), and International Society of Orthopaedic Surgery and Traumatology (SICOT). He serves on the editorial board of 6 journals, and is the guest editor of 3 journals and reviewer for over 70 journals. He serves as the organizing committee and executive chairs of the International Chinese Musculoskeletal Research Conferences (Shihezi, 2017; Suzhou, 2013). He has delivered more than 100 invited talks and is the author of 110 journal articles and 10 book chapters. His research interests include orthopaedic biomaterials, stem cells and tissue engineering, smart molecular recognition and controlled release, surface modification and functionalization, cellular biomechanics and mechanobiology.

Gang Li

 

bio

Huimin Li

Delivery of HAS2 by biodegradable nanoparticles to increase HA production.

 

bio

Supervisor: Pro. Xing Long
Education: Sep 2017 – Present School of Stomatology of Wuhan University, Wuhan, China, PhD. Major: oral and maxillofacial surgery
Summary:
Previous working is on the project of investigating the efficacy of MSN-CC-PEI system to deliver hyaluronan synthase 2 (HAS2) for increase high molecular weight HA synthesis. Skilled in various biological and molecular experiments, including cell and bacteria culture, western blotting, real-time PCR, plasmid construction, cell transfection, and the assays regarding angiogenesis, osteogenesis, adipogenesis, apoptosis and autophagy.
Basic scientific knowledge and understanding on statistics and logical writing.

Yingjie Li

Immunomodulatory role of macrophages in synovial chondromatosis of TMJ

 

bio

2004-2009 Pursuit for Bachelor's degree in Huazhong University of Technology
2009-2014 Pursuit for Ph.D in Wuhan University
2014-2018 Working at 2nd Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University.
2019-now Visiting scholar identity at Queensland University of Technology.

Yuncang Li

 

bio

Khoon Lim

 

bio

Khoon Lim

 

bio

Dr. Khoon Lim is a biomedical engineer with specialization in polymer chemistry (PhD awarded 2014). His research focus is on adopting a class of polymers known as hydrogels as tissue engineering matrices for a variety of applications. His research technology platform involves photo-polymerizable hydrogel bioinks for 3D bioprinting of functional tissues and also delivery of bioactive molecules to promote tissue regeneration. He has generated 22 high impact journal publications, four book chapters, 1 patent, as well as >80 conference proceedings. He has been awarded a total of >$1.7M research grant funding ($1.2M as PI), including the prestigious Emerging Researcher First Grant and Sir Charles Hercus Fellowship, both from the Health Research Council of New Zealand, and also a MARSDEN Fast Start Grant from the Royal Society of New Zealand. He has also won numerous awards including the Young Investigator Award from the International Society of Biofabrication. Dr. Lim is also currently an Associate Investigator on the Centre of Research Excellence in Medical Technologies (MedTech CoRE), Affiliate Investigator on the Maurice Wilkins Centre (MWC) for Molecular Diversity and Executive Committee member of the Australasian Society of Biomaterials and Tissue Engineering (ASBTE).

Khoon Lim

Tailoring physico-mechanical properties of bioinks for 3D extrusion bioprinting of vascularized constructs

 

bio

Dr. Khoon Lim is a biomedical engineer with specialization in polymer chemistry (PhD awarded 2014). His research focus is on adopting a class of polymers known as hydrogels as tissue engineering matrices for a variety of applications. His research technology platform involves photo-polymerizable hydrogel bioinks for 3D bioprinting of functional tissues and also delivery of bioactive molecules to promote tissue regeneration. He has generated 22 high impact journal publications, four book chapters, as well as >80 conference proceedings. In the last 5 years of his career, he has been awarded a total of >$2M research grant funding ($1.2M as PI), including the prestigious Emerging Researcher First Grant and Sir Charles Hercus Fellowship, both from the Health Research Council of New Zealand, and also a MARSDEN Fast Start Grant from the Royal Society of New Zealand. His research has also generated one full utility patent (US62/262245), now filed in Canada, China, New Zealand, Australia, America, Europe, South Korea), where he's the lead inventor. Dr. Lim is also currently an Associate Investigator on the Centre of Research Excellence in Medical Technologies (MedTech CoRE), Affiliate Investigator on the Maurice Wilkins Centre (MWC) for Molecular Diversity and Executive Committee member of the Australasian Society of Biomaterials and Tissue Engineering (ASBTE).

Rebecca Lim

 

bio

A/Prof. Rebecca Lim holds dual appointments at the Dept. of O&G at Monash University and Deputy Director of The Ritchie Centre, Hudson Institute of Medical Research. She is also an adjunct Research Group Leader at the Australian Regenerative Medicine Institute. A/Prof Lim pioneered the clinical use of allogeneic amniotic epithelial cells (hAEC). She led a dynamic team of biomedical and clinician scientists to completing a first-in-human hAEC trial in extremely premature babies with establish severe lung disease. She is currently involved in a further 5 approved hAEC clinical trials. She leads a cell manufacturing team responsible for GMP-compliant production, release and formulation of allogeneic hAECs for clinical use. A/Prof Lim has since progressed her work to developing a program of cell-free exosome-based therapeutics to address the challenges associated with logistics of clinical delivery, complexities of manufacturing and cost of goods in order to improve patient access and facilitate regulatory approval. This was the subject of her successful NHMRC Level 2 Industry CDF (2019-2022) where her application was rank highest in Australia, earning her a Research Excellence Award.

Chaozong Liu

Osteochondral scaffold innovation: from bench to clinic

 

bio

Chaozong Liu is a Professor of Orthopaedic Engineering, the programme leader of MSc in Musculoskeletal Science, and the group leader of UCL Orthopaedic Bioengineering Research Group within the Division of Surgery & Interventional Science University College London.

Professor Liu’s current research is directed toward the biomaterials processing and development of enhanced medical devices for treating musculoskeletal disorders, tissue repair and regeneration. His research in this area is supported by Arthritis Research UK, Innovate UK, Horizon2020, EPSRC MeDe Innovation Centre and RoseTree Trusts, and from Fitzpatrick Referrals Ltd. He has developed a new osteochondral scaffold technology that is likely to have a strong potential in regeneration of bone and cartilage for early intervention of osteoarthritis. A glimpse of how this scaffold will perform has been given, with promising results, by Professor Noel Fitzpatrick of the Channel 4 TV series Supervet, where it was implanted in a pet dog shoulder to treat a large osteochondral defect. His achievement in early treatment of osteoarthritis has recently been highlighted in Arthritis Toady (Nov 2017). The recent awards from Innovate UK-MoST and EU HORIZON2020 have significantly boosted his research in this field. The Versus Arthritis UK treatment sub-committee deemed the osteochondral scaffold “an exciting proposal with the potential to provide a novel intervention for a large number of patients and potentially provide good value for money for the health services” (dated 24 Oct 2017), awarded grant for first in man clinical trials in the Royal National Orthopaedic Hospital.

Guei-Sheung Liu

Innovative technology for genetic engineering in regenerative medicine

 

bio

Dr Guei-Sheung Liu is a Senior Research Fellow, Head of Genetic Engineering Laboratory at the Menzies Institute for Medical Research (Menzies) of the University of Tasmania and adjunct Principal Investigator of Ophthalmology at Jinan University, China as well as a senior fellow at the University of Melbourne (Ophthalmology, Department of Surgery). Dr Liu received his PhD in Biochemistry/Molecular Biology from Kaohsiung Medical University (Kaohsiung, Taiwan) working on the development of gene therapy for targeting neovascularization and neuroprotection. For over ten years, he has contributed to the design, development, and evaluation of innovative gene therapy approaches to prevent and delay blindness of major eye diseases. After joined the Menzies in 2017, Dr Liu’s work has extended from traditional gene therapy into the fields of genome editing, and a major focus of his ongoing work is to refine these applications to clear the hurdles impeding clinical translation. Moreover, his group also interests in the application of next-generation sequencing (NGS) technologies in for common, complex as well as rare ‘orphan’ ocular diseases. Dr Liu currently serves as the editor of the Journal of Gene Medicine and PLOS ONE.

Xing Long

The role of hyaluronan in joint disease with tissue engineering

 

bio

Dr. Long is a professor of Department of Oral and Maxillofacial Surgery, School of Stomatology, Wuhan University. Now he is the president of Chinese Society of TMD & Occlusion, CSA.He is an expert in Oral and Maxillofacial Surgery, especially in TMJ disease. He successfully performed thousands of oral and maxillofacial surgical procedures, conducted basic and clinical research. He has published many medical articles and edited or contributed several books. He has been invited as the keynote speaker in the international meetings.
He was a member of the Oral and Maxillofacial Surgery Society of the Chinese Stomatological Association from 1998 to 2012. Since 1997, he has been Vice President, China National Society of TMD & Occlusion and was a member of the Oral and Maxillofacial Surgery Society of the Chinese Stomatological Association.
Dr. Long received his dental degree in both medicine and dentistry (MD, DDS, Hubei Medical University) in 1983 and Ph.D. in Department of Oral and Maxillofacial Surgery, School of Stomatology, Hubei Medical University in 1997. He has a studying and working experience as visiting scholar at The Second Department of Oral Surgery, Tokyo Medical and Dental University, Tokyo, Japan in 1992, also as visiting scholar at Oral and Maxillofacial Surgery unit, University of Adelaide, South Australia in 2004.

Qiang Lu

Silk Biomaterials with Multiple Cues for Vascularization Capacity

 

bio

Qiang Lu, Full professor in Soochow University. Silk Biomaterials

Luis Malaver-Ortega

Harnessing the potential of functional genomics to uncover gene regulatory networks controlling cell behaviour

 

bio

Dr Luis F Malaver-Ortega finished his PhD studies at Monash University where he investigated the phenomenon of cellular reprogramming and pluripotency along with Professor Paul J Verma. After postdoctoral training in cell engineering at The Commonwealth Scientific and Industrial Research Organisation (CSIRO) and The Australian Institute for Bioengineering and Nanotechnology (AIBN) University of Queensland; he is currently serving as Research Fellow for the faculty of Pharmacy and Pharmaceutical Sciences at Monash University and manages the Functional Genomics Capabilities at The Monash Health Translational Precinct MHTP Melbourne, Australia.

Tony Manderson

Regulation of cell and tissue-based therapies in Australia

 

bio

I am currently the Head of the Cell & Tissue Therapy Unit at the Therapeutic Goods Administration in Australia. The Unit is responsible for regulating human cell and tissue-based products (known as biologicals). I first joined the TGA in 2007 and have worked in different areas, including the evaluation and testing of vaccines, regulation of blood and plasma-derived medicines, and most recently the regulation of human cell and tissue-based therapies (biologicals). Prior to this I worked as a post-doctoral research scientist at Imperial College in London and the Institute of Molecular Biosciences in Brisbane, with a focus on complement biology, autoimmunity and macrophage biology, after obtaining my PhD in Immunology from the Australian National University in Canberra, Australia.

Diego Mantovani

Surfaces and interfaces in regenerative medicine, with examples in tissue engineering, medical devices and cosmetics.

 

bio

Holder of the Canada Research Chair in Biomaterials and Bioengineering for the Innovation in Surgery, professor at the Department of Materials Engineering at Laval University, adjunct director at the Division of Regenerative Medicine of the Research Center of the CHU de Québec, Diego Mantovani is a recognised specialist in biomaterials. At the frontier between engineering, medicine and biology, within his team, their works aim to improve the clinical performances of medical devices for functional replacement, and to envisage the next generations of biomaterials to develop artificial organs enhancing the quality of the life of patients. He has authored more than 250 original articles, holds 4 patents, and presented more than 160 keynotes, invited and seminar lectures worldwide in the field of advanced materials for biomedical applications. His works received more than 7000 citations. In 2012, he was nominated Fellow of the International Union of Societies for Biomaterials Science & Engineering (FBSE) for his leadership and contribution to biomaterials for medical devices. He was Executive Co-Chair of the 10th World Biomaterials Congress 2016. He is advisor of three medical devices consortium in the Americas, Asia and Europe.

Mikael Martino

Growth factors engineered for enhanced binding to syndecans trigger tonic signalling and promote superior tissue healing

 

bio

Mikael Martino obtained his PhD in Biotechnology and Bioengineering at the Ecole Polytechnique Federale de Lausanne (EPFL) Switzerland, in 2011. During his PhD thesis, he principally focused on how the extracellular matrix regulates the activity of growth factors. Notably, he developed novel growth factor delivery systems for regenerative medicine applications including angiogenesis, chronic wounds and bone regeneration. Then, Mikael Martino received fellowships from the Swiss National Science foundation to do research in immunology at the Immunology Frontiers Research Centre, Osaka University, Japan. During postdoctoral training, he concentrated on how the immune system influences tissue repair and regeneration. Pursuing research at the interface between immunity and regenerative medicine, he became Assistant Professor at Osaka University in 2015. In mid 2016 Mikael Martino became an Associate Professor and EMBL Australia Group Leader at the Australian Regenerative Medicine Institute in Monash University, Australia. His laboratory try to understand how we can reactivate regenerative pathways by controlling the immune system. His team takes an interdisciplinary approach using genetic mouse models and bioengineering methods such as protein engineering and biomaterial functionalization. His long-term goal is to work at the interface between bioengineering and immunology to design novel regenerative medicine strategies.

Katsuhisa Matsuura

 

bio

Katsuhisa Matsuura is Associate Professor of Institute of Advanced Biomedical Engineering and Science, and Department of Cardiology, Tokyo Women’s Medical University (TWMU), Tokyo, Japan. In 1999, he graduated from National Defense Medical College and started cardiology training in TWMU Hospital. In 2006, he obtained his Ph.D. degree in TWMU. From 2009, he has developed the scalable bioreactor system for human iPS cell expansion and currently he is developing bioengineered human cardiac tissue for transplant and tissue model by the integration of cell sheet technology and iPS cell technology. Further as a physician scientist, he has been a member of academic societies such as The Japanese Circulation Society, American Heart Association, and a councilor of The Japanese Heart Failure Society and The Japanese Society of Regenerative Medicine.

Roberta Mazzieri

Preclinical Animal Models in TE&RM

 

bio

Dr Roberta Mazzieri obtained her PhD in Genetic Science from the University of Pavia (Italy) and subsequently undertook one post-doctoral position at the New York University (USA) and two at the San Raffaele Scientific Institute in Milan (Italy). Since her PhD studies, she focused on understanding the tumour microenvironment by examining a number of related molecular pathways including the uPA/uPAR system and TGFß1 activation. During her last postdoc with Prof. Naldini, she made her most significant and clinically-applicable contribution to cancer research by exploiting advanced gene transfer technologies to study the interplay between tumour associated macrophages and tumor angiogenisis. She demonstrated that targeting the ANG2/TIE2 pathway inhibits tumor angiogenesis, growth, and metastasis by disabling the pro-angiogenic activity of tumour associated Tie2-expressing macrophages (TEMs), thus impeding the emergence of evasive resistance to anti-angiogenic therapy. In 2011 this work was featured as cover article in Cancer Cell. Moreover, by turning TEMs into efficient delivery vehicles, she worked to target a key immune modulatory protein, IFN-alpha, to tumors and achieved substantial antitumor activity in several tumor models including a human model of breast cancer. This work was recently published as cover article in Science Translational Medicine. In 2012 she was nominated by the Young Ambassadors from the Metastasis Research Society (MRS) to speak at MRS meeting in recognition of her potential to launch independent research and contribute to high-quality publications. The same year she was recruited by the University of Queensland (Brisbane) to establish her own research group.
She is now continuing her work on targeting pro-tumoural macrophages to inhibit tumour progression with a specific focus on breast cancer metastasis. She is also continuing her work on demonstrating the therapeutic potential of turning tumour infiltrating macrophages into efficient delivery vehicles of anti-tumoural biomolecules.

Sally McArthur

 

bio

Sally McArthur is a Professor of Biomedical Engineering at Swinburne University of Technology and a CSIRO Research+ Science Leader in Biomaterials.
As an engineering researcher Sally has obtained approximately $22M in funding from research councils, industry and government in the UK and Australia, including the $1.8M ARC Industrial Transformational Training Centre in Biodevices launched at Swinburne in March 2015. She is passionate about exploring new ways to link industry and academia to create a new generation of entrepreneurial, innovative and internationally connected graduates capable of driving the Medical and Manufacturing sectors forward in Australia and internationally.
Sally is the Regional Director of the National Medical Device Partnering Program (MDPP), which launch in January 2019 with funding from Victoria’s Start-up Agency, LaunchVic. The program is an ideas incubator that supports inventors to turn their medical or assistive device ideas into proven concepts. We provide early stage development support to help de-risk, refine and develop ideas into commercially and technically viable prototypes. We do this by partnering clients with a community of experts including end-users and clinicians, manufacturers, service providers and world-class research partners and specialist facilities.
As a CSIRO Science Leader leads a team developing 4D Cell Culture Systems for biomaterials evaluation and testing. Based on tissue engineered models, her team aims to develop the materials, devices, monitoring tools and verification methods required to take translate these systems from the lab to industrial application.
Sally spent 6 years as a Lecturer and Senior Lecturer at the University of Sheffield in the UK after completing her Post-Doctoral Studies at the University of Washington in Seattle USA. She obtained her PhD from the University of New South Wales working with contact lens manufacturer Ciba Vision and CSIRO. She obtained her MEng Sci (Biomedical Engineering) and B.Eng (Materials Engineering) from Monash University.

Petra Mela

Elastin-like Recombinamers in Cardiovascular Tissue Engineering

 

bio

Geraldine Mitchell

 

bio

A/P Geraldine Mitchell’s (PhD. Univ of Melbourne) research for over 20 years has centred on vascularization projects related to reconstructive surgery. In the last 12 years she has worked on in vitro and in vivo tissue engineering of microcirculatory networks, wound healing angiogenesis, and implanted cell survival in in vivo tissue engineering models at the O’Brien Institute, Melbourne. Her current research focuses on vascularized liver tissue engineering, and the assembly of pre-vascularized scaffolds and tissue flaps for complex wound treatment. Her funding comes from the NH&MRC and a number of philanthropic sources.

Xiumei Mo

Electrospun nanofibrous bilayered scaffold for vascular tissue engineering

 

bio

Prof. Dr. Xiumei MO is a professor of Biomaterials in Donghua University. She once had two years Postdoc experience in Kyoto University, three years research fellow experience in National University of Singapore, one year visiting professor experience in Aachen University of Applied Science and Technology. In Donghua University she was granted 28 projects related with nanofiber fabrication for different tissue regeneration and hydrogel as tissue adhesive. She has published more than 300 papers. ISI Web of Science showed that she ranking No.7 in the world on electrospun nanofiber publication. She got the Science Technical Invention Awards from Shanghai Municipality in 2008. Science and Technology Progress Awards from State Department of Peoples Republic of China in 2009, Nature Science Awards from Shanghai Government in 2015. She is the committee members of China Biomaterials Society as well as Biomedical Engineering Society Biomaterials Branch. She is also vice chairman of China Composite Materials Society Super-fine Fiber Branch.

Xiumei Mo

Electrospun nanofibrous bilayered scaffold for vascular tissue engineering

 

bio

Prof. Dr. Xiumei MO is a professor of Biomaterials in Donghua University. She once had two years Postdoc experience in Kyoto University, three years research fellow experience in National University of Singapore, one year visiting professor experience in Aachen University of Applied Science and Technology. In Donghua University she was granted 28 projects related with nanofiber fabrication for different tissue regeneration and hydrogel as tissue adhesive. She has published more than 300 papers. ISI Web of Science showed that she ranking No.7 in the world on electrospun nanofiber publication. She got the Science Technical Invention Awards from Shanghai Municipality in 2008 Science and Technology Progress Awards from State Department of Peoples Republic of China in 2009, Nature Science Awards from Shanghai Government in 2015. She is the committee members of China Biomaterials Society as well as Biomedical Engineering Society Biomaterials Branch. She is also vice chairman of China Composite Materials Society Super-fine Fiber Branch.

Matteo Moretti

Complex 3D vascularized models for investigating heterotypic cell interactions within engineered pathological environments

 

bio

Matteo Moretti is the director of the Regenerative Medicine Technologies Laboratory at Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland and of the Cellular and Tissue Engineering Laboratory at the IRCCS Galeazzi Orthopedic Institute, Milan, Italy. He previously worked as a post-doc fellow at the Massachusetts Institute of Technology, Harvard-MIT Division of Health Science and Technology, Langer Lab. He obtained a European Doctorate in 2005 at Polytechnic of Milan, working also at the Tissue Engineering Laboratory with Prof. I. Martin, University of Basel. All of his titles, including B.Eng (Polytechnic of Milan) and M.Sc (Trinity College Dublin, with Prof. PJ Prendergast) are in Bioengineering.
His main research interests are within advanced cell culture technologies for musculoskeletal and cardiovascular tissues. In particular, he focused on engineering tissue complexity and in vitro models, including 3D tumor models, tissue microvascular networks and multi-scale bioreactor systems as key tools for viable and accessible cellularized therapeutic and diagnostic systems. Industrially, he has licensed one of his patents, has been coordinator of financed projects for Fidia Advanced Biopolymers (FAB, Abano Terme, Italy) and co-founder of 2 biotech start-ups (SKE s.r.l., Italy and Cellec A.G., Switzerland) focused on bioreactor technologies. His scientific awards include a N.A.S.A. Tech Brief Award for the development of scientific or technical innovations. He has been member of TERMIS since its foundation, co-founder of the SYIS section and then TERMIS-EU treasurer since 2015. He has authored more than 70 publications in peer-review impacted scientific journals.

Lorenzo Moroni

From Rapid Prototyping to Bioprinting: The Evolution of Additive Manufacturing Technologies for Biofabrication in Regenerative Medicine

 

bio

Prof. Dr. Lorenzo Moroni studied Biomedical Engineering at Polytechnic University of Milan, Italy, and Nanoscale Sciences at Chalmers Technical University, Sweden. He received his Ph.D. cum laude in 2006 at University of Twente on 3D scaffolds for osteochondral regeneration, for which he was awarded the European doctorate award in Biomaterials and Tissue Engineering from the European Society of Biomaterials (ESB). In 2007, he worked at Johns Hopkins University as a post-doctoral fellow in the Elisseeff lab, focusing on hydrogels and stem cells. In 2008, he was appointed the R&D director of the Musculoskeletal Tissue Bank of Rizzoli Orthopedic Institute, where he investigated the use of stem cells from alternative sources for cell banking, and the development of novel bioactive scaffolds for skeletal regeneration. From 2009 till 2014, he joined again University of Twente, where he got tenured in the Tissue Regeneration department.
Since 2014 he works at Maastricht University, where he is a founding member of the MERLN Institute for Technology-Inspired Regenerative Medicine. In 2016, he became full professor in biofabrication for regenerative medicine.
His research group interests aim at developing biofabrication technologies to generate libraries of 3D scaffolds able to control cell fate, with applications spanning from skeletal to vascular, neural, and organ regeneration.
In 2014, he received the prestigious Jean Leray award for outstanding young principal investigators from the ESB and the ERC starting grant. In 2016, he also received the prestigious Young Scientist Award for outstanding principal investigators from TERMIS. In 2017, he was elected as faculty of the Young Academy of Europe and in the top 100 Italian scientists within 40 worldwide by the European Institute of Italian Culture. Since 2019, he is chair of the Complex Tissue Regeneration department and vice-director of MERLN.

Nuno Neves

Nano-particles and -fibrous Scaffolds and Stem Cells for Advanced Therapies

 

bio

Nuno M. Neves is an Associate Professor at the Research Institute I3Bs on Biomaterials, Biodegradables and Biomimetics. This is a research unit of Excellence, directly funded by the Portuguese Foundation for Science and Technology (FCT). The 3B’s Research Group integrates the PT Associate Laboratory ICVS/3B’s, as homologated by the Portuguese Ministry for Science and High Education, being Nuno M. Neves one of the members of the Board of Directors. He is the Director of the FCT Doctoral Program in Advanced Therapies for Health (PATH) and the Director of the Integrated Master Course of Biomedical Engineering of the University of Minho. He is also the Erasmus Academic coordinator for the Biomaterials, Rehabilitation and Biomechanics branch of the Integrated Master Course of Biomedical Engineering of the University of Minho.
As of April 2019, he is the author of 177 publications listed in the Web of Science (135+ peer reviewed international papers), with h-factor of 39 and a total number of citations of over 4750 (h:38;4600 in Scopus).
He is an elected member of the Board of Governors of the European Society for Artificial Organs and is currently the responsible for the Tissue Engineering Working Group of the ESAO.

Yanhong Ni

SPARC Promotes proliferation and metastasis of OSCC

 

bio

Associate Researcher: (December, 2017-Now) Central laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing 21008, Jiangsu Province, China
Assistant Research Fellow: (October, 2010~November, 2017): Central laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing 21008, Jiangsu Province, China
Research Assistant: (August, 2008-September, 2010) Central laboratory, Nanjing Stomatological Hospital, Medical School, Nanjing University, Nanjing 21008, Jiangsu Province, China

Fazlina Nordin

 

bio

Fazlina Nordin received her BSc. degree in Microbiology with Honor from Universiti Kebangsaan Malaysia (UKM) in 2002, and M.Med.Sc. (Pathology) degree in 2006. She pursues her higher education at King’s College London, UK and awarded a Ph.D degree in 2012, specialized in cancer studies. She received a National Science Fellowship (NSF) scholarship, a privilege scholarship from Ministry of Science, Technology and Innovation of Malaysia, and a fellowship of Academic Staff Training Scheme (ASTS) from Ministry of Higher Education of Malaysia for her master, and Ph.D degrees respectively. Currently, she is a research fellow and senior lecturer at Tissue Engineering Centre (TEC), UKM Medical Centre (UKMMC), Malaysia. She is also a treasurer and executive member of Tissue engineering and Regenerative Medicine Society of Malaysia (TESMA).

She studied on haematopoietic stem cell (HSC) during her Ph.D, finding ways to expand the numbers of HSC without genetic modification for safer clinical applications. Since then, stem cell niche has become her research interest, including working on induced pluripotent cell (iPSC), mesencyhmal stem cell (MSC), and cord blood (CB). She also involves in lentiviral construction and production for gene therapy, both protein and lentiviral transduction systems, cell biology and molecular research.

She is also involved with national and international research collaboration, and has been invited as speaker, panel, chairperson and judge in a few conferences, seminars and meetings. In addition, she was also one of the young scientists involved in the ‘Angkasawan’ a privilege national project of Malaysia in 2007, sending cells to space to study the effect of microgravity and radiation to eukaryotic cells. In addition, she also has organized numerous of conferences and meetings at national and international level.

Andrea O'Connor

 

bio

Professor Andrea O’Connor, BE(Hons), PhD, FIChemE is the Head of the Department of Biomedical Engineering and leads the Tissue Engineering Group at the University of Melbourne. She was a Fulbright Scholar at Massachusetts Institute of Technology in 1995-96. Her research is focussed on design, synthesis and fabrication of biomaterials, porous materials and antimicrobial nanomaterials. She is particularly interested in strategies for scale-up of tissue engineering including vascularisation, and design of antimicrobial materials for medical implants. She has published over 80 journal articles, co-authored the chapter on Tissue Engineering for the major reference work ‘Plastic Surgery’ edited by Neligan and Gurtner, lectured on tissue engineering and biofabrication at the Bayreuth International Summer School, Germany, and was a finalist in the 2017 Graeme Clark Institute HealthTech Innovation Challenge. Andrea also led the engineering team on the world-first Neopec clinical trial of breast reconstruction using tissue engineering, showing proof-of-principle of tissue engineering of large volumes of well vascularised fat tissue. She collaborates with a range of hospitals, medical research institutes and medical device companies to improve existing products, develop new devices and solve clinical problems.

Joaquim Miguel Oliveira

Gellan gum-based hydrogels for cartilage tissue engineering and bioprinting

 

bio

J. Miguel Oliveira, BSc, PhD is a Principal Investigator “Investigador FCT 2012 and Investigador FCT 2015” at the Associate Laboratory ICVS/3B’s (http://www.3bs.uminho.pt/users/migueloliveira) and has been involved in several projects regarding biomaterials development for tissue regeneration, mainly polymers from natural origin (e.g. silk-fibroin) and ceramics (e.g. tricalcium phosphate). Since Dec. 2018, he is Vice-President of I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics of University of Minho. Along the years, he has focused his work on the field of tissue engineering, nanomedicine, stem cells and cell/drug delivery. As result of his proficiency, he has published so far more than 250 scientific contributions in scientific journals with referee (some in high impact factor journals), being 9 of those review papers produced under invitation. Miguel Oliveira was approved 16 patents and published 5 books (plus 3 in preparation), 2 special issues in scientific journals, 80 book chapters in books with international circulation, on international encyclopedias, and science dissemination. He has great experience in intellectual property rights and patent exploitation. He has participated in near 300 communications in national/international conferences. Due to his expertise, he participated as invited/keynote speaker in more than 50 plenary sessions. As off March, he has an h-index of 35, i10 of 84, receiving ~ 5200 citations; and has an RG-index of 43.89. He has been awarded several prizes including the Jean Leray Award 2015 from European Society of Biomaterials for Young Scientists for Outstanding Contributions within the field of Biomaterials. He has a great experience in what concerns with the supervising of both undergraduate and graduate students both related with practical (laboratory) and theoretical issues related with Nanotechnology applied to Tissue Engineering and Regenerative Medicine namely, for muscle, bone, cartilage, osteochondral tissue, peripheral nerve, meniscus and intervertebral disc (IVD) regeneration. More recently, he set-up a new research line within the PT PT Government Associate Laboratory ICVS/3B’s on nanoparticles systems for theranostics and cancer research (Colorectal cancer and brain tumours). In this respect, Miguel Oliveira has been contributing with 15 years of experience in academia. As a researcher at the 3B’s, he has been very active on the elaboration and management of several national (e.g., QREN, FCT) and EU funded projects (National and European, Hippocrates, Expertissues, etc, please see http://www.3bs.uminho.pt/), and took part of the organization of several scientific meetings (e.g., InVents-Series of events and the 2008 Annual Meeting of Tissue Engineering and Regenerative Medicine-European Chapter), and in the development of the business plan of STEMMATTERS, which is the biotechnological spin-off of the 3B’s Research Group. He has been also involved in the supervision of several under-graduated students (e.g., Biomedical Engineering, Applied Biology, Polymer Chemistry, and Health Sciences: School of Medicine at Univ. of Minho and University of Algarve) and mentoring during training courses (e.g., INVENTSCIENCE, http://www.inventscience.org/ and MIT-Portugal). He was one of the mentors of the new facilities of the 3B’s Research Group and the Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine at Avepark, Caldas das Taipas - Guimarães, Portugal. In addition, he is member of the advisory board of the Journal of Materials Science: Materials in Medicine, Bio-Design and Manufacturing Journal, International Journal of Tissue Engineering, Journal ISRN Biomaterials, The Journal of Experimental Orthopaedics, Journal “Recent Patents on Corrosion Science”, and referee in ~45 international journals.

Hongwei Ouyang

 

bio

Haobo Pan

 

bio

PROF. HAOBO PAN completed his PhD studies at the University of Hong Kong in 2007, and carried out his postdoctoral research at the Li Ka Shing Faculty of Medicine in the University of Hong Kong from 2008 to 2010. In 2010, he promoted to Research Assistant Professor at the Department of Orthopaedics and Traumatology in the University of Hong Kong. In 2012, he was appointed as the Director of the Research Center in Human Tissues and organs Degeneration, Shenzhen Institute of Advanced Technology, Chinese Academy of Science. Later, he was promoted as the Vice Director of the Institute of Biotechnology and Biomedicine and appointed as the Director of Shenzhen Key laboratory in Marine Biomaterials and the Director of Technology Center of Guangdong Province Marine Biological Materials Engineering. Now, he is appointed as Vice Director of the National Unit of Orthopaedic Biomaterials in China. His current research activities are focused on material chemistry, biomaterial synthesis and modification, marine biotechnology, biomaterial zoology and clinical assessment. He has published more than 100 papers in qualified international journals and served as board member of ISRN Biomaterials and Journal of Osteoporosis and Physical Activity.

Eun Soo Park

Aesthetic correction of nasal lobule using 3D PCL meshes

 

bio

Plastic Surgeon

Laura Poole-Warren

Materials (Functional Biomaterials and Surfaces for Biomedical Applications)

 

bio

Professor Laura Poole-Warren leads a research group in Biomedical Engineering at UNSW Sydney focussed on design and development of biomaterials for cell and drug delivery in soft and excitable tissue applications. Key research projects include:
Design and development of novel neural interfacing materials for neural stimulation and recording electrodes (conducting polymers, hydrogels and cell-based electrodes - cell-electrodes)
Understanding neuro-compatibility compatibility of new materials with nervous tissues
Development of 3D mixed cell cultures and organoids for evaluating neural responses to technology
Laura has developed intellectual property in soft, conductive neural interfacing materials that can be applied as an electrode coating or freestanding conductive material. She has held appointments as visiting research professor at Rutgers University in the USA and as a preclinical scientist in the biomedical industry working on development of implantable devices including wound dressings and embolic agents for cancer treatment. She also has expertise in regulatory requirements for medical technology having served for 10 years as a member of the Australian Commonwealth Government statutory Advisory Committee on Medical Devices (ACMD) advising the Therapeutic Goods Administration on the safety of medical devices. She has been elected as a Fellow of three academies, ATSE, AIMBE and IUSBSE and is an Associate Editor of the leading journal in her field, Biomaterials and on the editorial board of the Journal of Neural Engineering.

Amirali Popat

 

bio

Dr Amirali Popat is currently Senior Research Fellow at The School of Pharmacy, The University of Queensland. His group’s research interests include the design of programmable nano formulations for personalised treatment of Inflammatory Bowel Disease, Cancer and Diabetes. His research on smart nanoparticles has attracted approximately ~ $ 4.5 million in the past 5 years. Dr. Popat has an exceptional track record and international standing in the area of novel drug delivery systems evidenced by 30 peer reviewed publications and 2 patents. Most of these publications are in top tier journals in the fields of Chemistry (Angweandte Chemie, Chem Comm), Biomaterials (Biomaterials, Nanoscale), and Pharmaceutical Science (Mol Pharm, Int J Pharm, J Colloids & Interface Sci). Together these have a combined ISI I.F of >150 with ~1500 citations (Google scholar) with an H-Index of 19. Testimony to his excellence in research, teaching and community engagement he has received many awards notably 2018 QLD Young Tall Poppy Science Award and Faculty Early Career Research Excellence Award.

Jean-Michel Pouvesle

Plasma/target interactions in biomedical applications of cold atmospheric pressure plasmas: Implications for dose regulation in treatments.

 

bio

Jean-Michel Pouvesle received the Ph.D and the Doctorat d’Etat degrees in plasma physics from the University of Orléans, France, in 1981 and 1986 respectively. He is currently a CNRS Senior Scientist working in GREMI, joint laboratory from the CNRS and University of Orléans, of which he has been Director from 2003 to 2011. He has been director of the French Research Network ABioPlas which gathered most of the laboratories working in the field of biological applications of plasmas from 2011 to 2017. His research interest includes fast electrical discharges, non-equilibrium atmospheric pressure plasmas and related plasma kinetics, reactive species production, plasma flow control, plasma cosmetics, plasma agriculture and plasma medicine. He is co-author of more than 160 peer review papers and 10 patents. So far, he gave 85 international (among them 12 plenaries) and 21 national invited talks at conferences and symposia, among more than 300 contributions. He has supervised 25 PhD students and many post-docs and young researchers. He has been involved in more than 50 industrial or academic grants. He has also been involved in more than 30 Organizing Committees or International Scientific Committees of conferences and organized or co-organized himself 8 national or international conferences. JM Pouvesle is one of the 28 Fellows of the International Plasma Chemistry Society. He has been the president of this society over the period 2006-2007. He has also been the President of the International Society for Plasma Medicine over the period 2013-2014. He has been (2011-2015) Work Group leader of “Plasma therapeutics” and member of the Steering Committee of the European COST MP 1011 Biomedical Applications of Atmospheric Pressure Plasmas. He recently got the Plasma Medicine Award (Sept. 8 2016) from the International Society for Plasma Medicine.

Indira Prasadam

Regenerative Medicine for Osteoarthritis

 

bio

Jelena Rnjak-Kovacina

 

bio

Dr Jelena Rnjak-Kovacina is a Senior Lecturer and Heart Foundation Future Leader Fellow researcher at the Graduate School of Biomedical Engineering, UNSW Sydney. Her research interests are at the interface of biology and engineering, focusing on the development of biomimetic silk fibroin-based biomaterials that direct cellular interactions for enhanced vascularisation and treatment of cardiovascular disease. She completed her doctoral degree in Anthony Weiss' lab at the University of Sydney, and her postdoctoral training in David Kaplan’s group at Tufts University in Boston. She is the receipt of a number of awards recognizing her contributions to the biomaterials and tissue engineering field, including the Bob Fraser New Investigator Award from the Matrix Biology Society of Australia & NZ, the Young Tall Poppy Science Award from the Australian Institute of Policy and Science, and the Early Career Award from the Australasian Society for Biomaterials and Tissue Engineering (ASBTE). She participates in the MedTech sector through a range of activities including her role as the Treasurer and Secretary of ASBTE.

Dr. Zhu Rongrong

Layered Nanomaterials Promote the Self-renew of Stem Cells and Accelerate Neural Regeneration (tentative title)

 

bio

Dr. Zhu Rongrong received her bachelor degree and Ph.D. from Tongji University, Shanghai, China. She worked as Postdoctoral Associate at Stoney Brook University, New York, United States from 2009-2010. Dr. Zhu is now a Professor at School of Life Science and Technology, Tongji University, Shanghai, China. Prof. Zhu’s researches focus on the field of ‘Regenerative Medicine and Nanomaterials’ to regulate the microenvironment of injury site and promote the neural regeneration. Previously, she had discovered the new functions and their mechanisms of nano-layered double hydroxides (LDH) and graphene oxide (GO) on maintaining self-renewal and of stem cells and inhibiting inflammatory response (Biomateirals 2015, 2018; Nanoscale 2018); and she had Constructed a novel composite nanomaterial, LDH@SiO2-Bev, which could target membrane receptor and achieve specific multistage targeting (Adv. Sci. 2016, Cover article; Acta Biomater. 2016,2017). Dr. Zhu’s research interests also include using artificial intelligent technologies to facilitate the biomedical studies, she had developed an intelligent drug screening system ‘DeepScreen’ established on deep learning and single-cell imaging by flow cytometry (Adv. Sci. 2018) , by which nano-drugs were obtained for central nervous system repair.

Iman Roohani

 

bio

Dr Roohani was awarded his Ph.D. degree in 2014 (in Biomedical Engineering, Biomaterials and Tissue Engineering) from University of Sydney. In 2016, he was awarded prestigious National Health and Medical Research Council early career fellowship and in 2017, he moved to University of New South Wales to establish “Biomaterials Design and Tissue Engineering” lab. His research group is interested in investigating cell-biomaterial based strategies for musculoskeletal tissue regeneration and their application in the clinical translation of orthopaedic medical devices. The research technology platform involves 3D biofabrication and additive manufacturing of biomaterials and medical devices applied to regenerative medicine of bone, and development of novel nanocarriers and bone grafts to promote bone healing or treat bone diseases. He holds 2 registered patents and has published more than 50 peer reviewed articles and book chapters. One of his inventions, a novel bioceramic ceramic bone graft, is currently being commercialised by an Australian medical device company. He has attracted over AUD$1.7 million in competitive research funding as a principal or co-investigator through grants from national and international funding bodies e.g. NHMRC, AO foundation Switzerland and DAAD German Academic Exchange Service. He is an editorial member and guess editor for several ISI journals and his research have thus far led to 20 national and international awards.

Jeroen Rouwkema

Creation of multi-scale vascular networks in engineered tissues

 

bio

Jeroen Rouwkema received his PhD in Regenerative Medicine from the University of Twente, the Netherlands, in 2007 under the supervision of Prof. Clemens van Blitterswijk. As a preparation for his PhD thesis, he worked for 6 months in the Langer lab at MIT. He has gained further experience at Keele University (Prof. Alicia El Haj) and Harvard Medical School (Prof. Ali Khademhosseini). He is currently an Associate Professor at the Department of Biomechanical Engineering, University of Twente, where he leads his own group focusing on vascularization of engineered tissues. He is a tissue engineer with an extensive experience in this field, having focused on the vascularization of skeletal muscle, bone, and cardiac muscle tissue. To optimize the organization and maturation of vascular networks, he combines tissue engineering technology with mechanical and chemical stimulation, computational modeling and biofabrication. He has received several personal scholarships, including a VENI scholarship (2011-2014), a Marie Skłodowska-Curie International Outgoing Fellowship (2014-2017) and an ERC Consolidator Grant (2017-2022). In 2017 he received the TERMIS EU Robert Brown Early Career Principal Investigator Award in recognition of his achievements.

Katsuhisa Sakaguchi

 

bio

Katsuhisa Sakaguchi is Associate Professor at Waseda University of Tokyo and Research Associate at Tokyo Women’s Medical University. He received Ph.D. in Bioscience and Biomedical Engineering from Waseda University in 2010. He graduated from the Department of Mechanical Engineering, Waseda University in 2002 and received M. Eng. in 2004. His research interests are the engineered 3D tissue for the regenerative medicine and the food using mechanical devices such as the perfusion system, the floating rotation system, the 3D bioprinting. In addition, he has an interest in device development to evaluate the condition of engineered tissue, such as the optical coherence tomography and the optical glucose measurement technology.

António Salgado

The Proteic and Vesicular Secretome of Cells in Regenerative Medicine

 

bio

António Salgado is a biologist with a PhD in Tissue Engineering and Hybrid Materials (2005, University of Minho), and a Habilitation (DSc) in Health Sciences (2018, University of Minho). Currently he is a PrincipaI Investigator at the Life and Health Sciences Research Institute (ICVS) and an Adjunct Associate Professor in the School of Medicine, University of Minho. His research interests are focused on the development of innovative therapies for CNS repair, namely on Spinal Cord Injury and Parkinson’s Disease. His main areas of research are: 1) Development of ECM like hydrogels for the transplantation of Mesenchymal Stem Cells into the injured CNS; 2) Role of the secretome of MSCs in neuroprotection and repair, particularly the establishment of novel therapies based on the sole use of MSCs secretome. His lab has successfully introduced the use of peptide grafted gellum gum based hydrogels for spinal cord injury regenerative medicine. Simultaneously it has also made important contributions for the characterization and use of therapies based on stem cells secretome for CNS repair. He is an author of more than 100 papers (over 3500 citations; h-Index=29, Clarivate Analytics Web of Science), and has delivery over 50 invited talks worldwide Presently he is the coordinator of the Portuguese Network for Spinal Cord Injury Research and director of the Spinal Cord Injury Initiative @ ICVS (SCICVS). He serves as an Associate Editor for Biomed Research International, Biochimie, BMC Neuroscience and Stem Cells International. He has received several distinctions for his work including the Gulbenkian Award on Cutting Edge Research in Life Sciences, and the Prize Melo e Castro for Spinal Cord Injury Research, awarded by Santa Casa de Misericordia de Lisboa (2013 and 2017).

Dr. Carlos Salomon

 

bio

Dr Carlos Salomon is a group leader and senior Lions Medical Research Foundation (LMRF) Fellow working at the University of Queensland Centre for Clinical Research (UQCCR). Prior to joining UQCCR, Dr Salomon completed his Bachelor Degree in Biochemistry and a Masters degree in Clinical Biochemistry and Immunology at Universidad de Concepcion (Chile) and a PhD in Medical Science at Pontifical Catholic University of Chile. He has been the author of more than 50 journal publications during the period 2011-2016, many of which appear in high-ranking journals in the field (e.g. Diabetes, JCEM, Placenta and FASEB). He is recognized as a national and international researcher working in the field of extracellular vesicles focusing on the reproductive biology (specifically in pregnancy and its complications) and has been consistently invited as a speaker to both National and International meetings (e.g. Australasia Extracellular Vesicles Society 2014 and International Society for Prenatal Diagnosis 2014). Within UQCCR, he has established and lead the EXOSOME BIOLOGY LABORATORY that conforms the ISO standards (ISO17025 and 13485), in which human exosomes can be isolated, characterised and their role elucidated to evaluate their clinical utility as biomarkers of disease and therapeutic interventions.

Abel Santos

 

bio

Dr. Abel Santos received his BEng in Chemical Engineering from the Universitat Jaume I (Spain) in 2006, and MEng and PhD degrees in Electronic Engineering from the Universitat Rovira i Virgili (Spain) in 2007 and 2011, respectively. In 2014 he was awarded an ARC-DECRA, and currently he is a ‘Research for Impact’ Fellow and Senior Lecturer in the School of Chemical Engineering, member of the Institute for Photonics and Advanced Sensing (IPAS), and associate investigator of the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP) at the University of Adelaide, where he works on structural engineering of photonic crystals based on nanoporous anodic alumina.

Karl-Heinz Schuckert

Bone Development in vertical Dimension - a special Challenge in Oral Surgery

 

bio

Karl-Heinz Schuckert received his Ph.D. degree from Hanover Medical School after his studies of medical science and dentistry. He specialized in dental surgery and TMJ (temporomandibular joint disorder). In 1982 he set himself up as a dental surgeon in a private practice in Hanover. There he also established the Institute Indente, Centre for Tissue Engineering. In 2008 he initiated the first Bone-Tec Congress, which took place seven times till 2017. His research work concentrated on the following subjects: soft tissue engineering, bone tissue engineering, TMJ (temporomandibular joint disorder), antimicrobial photodynamic therapy. Karl-Heinz Schuckert developed new techniques in oral surgery especially in the management of soft tissue using endoscopically assisted surgery and in increasing new bone in vertical dimension. On these subjects he published and presented a large number of talks. In 2011 he initiated together with Prof. Teoh the TERMIS Group Musculoskeletal TE and chaired this till 2016. He is a member of a number of scientific associations.

Hidekazu Sekine

In vivo vascularization for tissue and organ fabrication

 

bio

Previously, I received my training in clinical radiology at the International University of Health and Welfare (Tochigi, Japan) and at the hospital of Tokyo Women’s Medical University. Now, I am Assistant Professor in the Institute of Advanced Biomedical Engineering and Science at Tokyo Women’s Medical University. My current research is on myocardial tissue reconstruction using the concept of cell sheet-based tissue engineering. In particular, my focus is based on using various methods for creating vascularized tissues in order to engineer thicker, functional tissue grafts. Recently, my work has been in the creation of cardiac tissues that resemble the native heart, but can function independently, in an effort to move from tissue engineering towards organ engineering.

Abbas Shafiee

Novel Innovations in Cell Transplantation and Angiogenesis

 

bio

Dr. Abbas Shafiee is a PhD specialized in stem cell biology, and tissue engineering with over 12 years combined research experience in academia and biotechnology industry. The focus of his research is to develop translational cell-based and tissue engineering approaches to treat cardiovascular and cancer diseases.
Dr. Shafiee completed his PhD at The University of Queensland Centre for Clinical Research (UQCCR). His PhD study focused on the in vivo definition of endothelial progenitor cells (EPC) from the human placental tissues. As a result of this project, he established a new in vivo hierarchy amongst EPCs. He also identified the bipotential precursors, Meso-Endothelial cells, in the human placenta which programmed to give rise to both mesenchymal and endothelial stem/progenitor.
After finishing PhD, he joined Centre in Regenerative Medicine (CIRM), QUT and conducted a project on investigation of cancer bone metastasis using modelomics approach with distinguished professor Dietmar Hutmacher. At CIRM, they have developed a new cutting edge research area, humanized animal models, via the translation of tissue engineering technologies into cancer research. They have utilized the humanized animal models as platforms to study species-specific cancer bone metastasis and develop and test new therapeutic strategies.

Jin-Hyung Shim

Three-dimensional Bioprinting using Tissue-specific Decellularized Extracellular Matrix

 

bio

Assistance Professor in Mechancial Engineering and CTO of T&R Biofab

Tatsuya Shimizu

Cutting edge of 3-D assembly technology for clinical application

 

bio

I am now director & professor of Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University (TWMU). I graduated from Faculty of Medicine, the University of Tokyo and got medical doctor (M.D.) in 1992. After two-year clinical training, I made a specialty of cardiovascular medicine including catheterization and got Ph.D in 1999. After that, I moved to TWMU and started tissue engineering research based on “cell sheet technology” especially for heart regeneration. Now, my recent work is engineering various types of functional 3-D tissues & organs for regenerative therapy, drug screening and food fabrication.

Tiago Silva

 

bio

Tiago H. Silva (39 years old) is Senior Researcher at 3B’s Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, from University of Minho (Portugal), member of ICVS/3B’s Associated Laboratory, being coordinator of Marine Inspired Biomaterials research line.
He holds a PhD in Chemistry (2006, Faculty of Sciences – University of Porto, Portugal) on surface modification by electrostatic layer-by-layer self-assembly of polyelectrolyte multilayers.
His research focus on the development of marine inspired biomaterials for regenerative medicine strategies, namely for tissue engineering and advanced therapies addressing diabetes and cancer. His team has established methodologies for the production of biopolymers (marine origin collagens, squid chitosan, fucoidan) and ceramics from marine resources and derived byproducts and their processing as biomaterials using different technologies, as freeze-drying, photocrosslinking or 3D printing.
Marine biomimetics is also being explored, looking into functional proteins enrolled in collagen aggregation and bioadhesion, as well as to hierarchical morphologies observed in marine sponges and diatoms, as inspiration for the design of innovative biomedical applications and smart materials.

Tiago Silva

Marine Biotechnology on Tissue Engineering: some key-enabling tools

 

bio

Tiago H. Silva (39 years old) is Senior Researcher at 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, from University of Minho (Portugal), member of ICVS/3B's Associated Laboratory, being coordinator of Marine Inspired Biomaterials research line.
He holds a PhD in Chemistry (2006, Faculty of Sciences - University of Porto, Portugal) on surface modification by electrostatic layer-by-layer self-assembly of polyelectrolyte multilayers.
His research focus on the development of marine inspired biomaterials for regenerative medicine strategies, namely for tissue engineering and advanced therapies addressing diabetes and cancer. His team has established methodologies for the production of biopolymers (marine origin collagens, squid chitosan, fucoidan) and ceramics from marine resources and derived byproducts and their processing as biomaterials using different technologies, as freeze-drying, photocrosslinking or 3D printing.
Marine biomimetics is also being explored, looking into functional proteins enrolled in collagen aggregation and bioadhesion, as well as to hierarchical morphologies observed in marine sponges and diatoms, as inspiration for the design of innovative biomedical applications and smart materials.

Steven Stacker

 

bio

Prof. Steven Stacker is head of the Tumor Angiogenesis and Microenvironment Program at the Peter MacCallum Cancer Centre in Melbourne. Previously he worked for two decades at the Melbourne Branch of the Ludwig Institute for Cancer Research, an international Cancer Institute where he was Associate Branch Director and Joint-Head of the Angiogenesis Laboratory. He received his Ph.D. from the University of Melbourne in 1988 on work characterising mucins associated with breast cancer and subsequently developing serum markers for the diagnosis of breast cancer. He undertook post-doctoral training with Prof. Timothy Springer at the Dana-Farber Cancer Institute and Centre for Blood Research, Harvard Medical School, Boston from 1988-1991. He has published more than 150 articles and 30 patents in the area of vascular biology, cell adhesion and tumour detection. He is recognised internationally for his work on identifying new members of the growth factor family that control vessel formation. He demonstrated that the growth factor VEGF-D can stimulate new lymphatic vessels and promote lymphatic metastasis providing a potential pathway to block tumour metastasis. His work has contributed to the formation of three companies, Integrated Medical Technologies, Lymphatix Ltd and Vegenics Ltd. which focused on developing therapeutics and biomarkers for vascular disease and cancer. Prof. Stacker was the inaugural holder of the Pfizer Australia Senior Research Fellowship and is currently supported by an NHMRC Research Fellowship and Project Grant. His current work tries to understand the unique signalling pathways in lymphatic endothelial cells with the aim of identifying new targets for therapeutics in vascular disease and cancer.

Colin Stewart

 

bio

Colin Stewart has been a pioneer in developing many of the techniques, such as producing stem cell chimeras, that are now widely used in mouse experimental genetics, in establishing protocols for deriving embryonic stem (ES) lines, uniparental ES lines, and for the derivation of the first human ES lines. He was instrumental in identifying the cytokine LIF as being crucial to sustaining stem cell pluripotency (Nature 1988). Subsequently he showed that LIF and its signalling pathway is critical to regulating uterine receptivity for embryo implantation in mammals (Nature 1993). He developed numerous mouse models of congenital diseases, particularly those arising from defective genomic imprinting e.g. Prader-Willi. Over the last decade his interests have centred on the laminopathies, a heterogeneous collection of diseases all arising from mutations in the LaminA gene. He collaborated with Nicolas Lévy, in being the first to show that mutations in the LMNA gene cause progeria (premature ageing) (Science 2003), and to make mouse models of many of the laminopathies, including progeria. He also developed the first iPSCs lines derived from patient fibroblasts in establishing an in vitro model for Progeria (HGPS). Currently, he is a founding partner of Daedalus Therapeutics that is developing new treatments to ameliorate cardiomyopathies and vascular disease.

Wei Sun

 

bio

Dr. Wei Sun is Albert Soffa Chair Professor of Mechanical Engineering, Drexel University, and National “Thousand-Talent” Distinguished Professor and Director of Biomanufacturing Research Center, Tsinghua University, Beijing, China. Dr. Sun’s research has been on Biofabrication, 3D Bio-Printing, Computer-Aided Tissue Engineering, CAD/CAM, and Additive Manufacturing. His research has been sponsored by the US National Science Foundation (NSF), Defense Advanced Research Projects Agency (DARPA), National Aeronautics and Space Administration (NASA), National Institute of Standard and Technology (NIST), Army Research Laboratory (ARL), and Johnson & Johnson (J&J), the Chinese Natural Science Foundation, the Chinese Ministry of Science and Technology, and the Chinese Ministry of Education. Dr. Sun has published over 550+ journal and conference papers/abstracts, 50+ patent applications, and conducted 320+ invited national and international presentations in the field of his research.

Dr. Sun is the Founding President for International Society of Biofabrication (2010-2014), and the Founding Editor-in-Chief for international journal Biofabrication (2009-present). He has also served technical reviewer for Science, Nature, and other 50+ scientific journals, an annual proposal reviewer and panelist for NSF, NIH, CNSF, and Research Councils of UK, EU, Korea, Hong Kong, Canada, and Singapore. Dr. Sun received Award of Distinguished Visiting Fellow from the Royal Academy of Engineering in UK (2018), the Senior Investigator Award from International Society of Biofabrication (2017), MII / Fralin Visiting Scholar Award from Virginia Tech (2015), Outstanding Research Award, College of Engineering, Drexel University (2009), William Mong Fellow Award, the University of Hong Kong (2008) and Ralph R. Teetor Educational Award, International Society for Automotive Engineers (2003).

Gerard Sutton

 

bio

Professor Sutton is a corneal specialist and ophthalmic surgeon with more than 20 years’ experience. He remains the recipient of the Douglas & Lola Douglas Chair of Clinical Ophthalmology and Eye Health at Sydney Medical School, The University of Sydney. Confirming his experience and international standing in the treatment of corneal disease he was first Australian to be appointed to the council of the Asia Corneal Society till now. He is currently the Medical Director of the NSW Organ & Tissue Donation Service (Lions NSW Eye Bank), the Head of the Corneal Unit at Sydney Eye Hospital and more recently the Medical Director of the Australian Ocular Biobank. He is a member of several organising committees including Australian Council on Safety and Quality in Health Care. Prof Sutton has published over hundreds of peer-reviewed articles with a total number of citations number of1,674 as of January 2019 (Scopus). He initiated the development of a novel biomaterial for treating corneal epithelial defects, named the iFix system. Prof Sutton has been instrumental in building a collaboration with Prof Gordon Wallace (CIB) and his team at University of Wollongong to further develop the iFix range of products. In 2019 he co-created iFix Medical to further support translational research into corneal disease. He is also the founder of the Australian Corneal Bioengineering working group which brings together researchers within the field for consultation and discussion regarding research in the field.

Tetsushi Taguchi

Development of Hydrophobically-modifed Fish Gelatin-based Adhesive for Biomedical Applications

 

bio

Prof. Tetsushi Taguchi received his Ph.D. from Kagoshima University in 1999 majoring in Biomaterials and did postdoctoral research until 2002. He became Researcher in 2002 at Biomaterials Center, National Institute for Materials Science (NIMS), Japan. He became Director of Bioadhesive Materials Technology Center in October, 2015. He was promoted to Group Leader in April, 2016. He is also Professor of Department of Materials Science and Engineering, Graduate School of Pure and Applied Science, University of Tsukuba, Japan. His research interests include tissue adhesive materials, bioadhesive interface, injectable gels, tissue engineering and regenerative medicine. He has authored more than 120 publications and holds 32 issued patents. He is Managing Editor of Journal of Artificial Organs.

Hironobu Takahashi

Maturation in skeletal muscle tissue engineering.

 

bio

I am now an associate professor of Institute of Advanced Biomedical Engineering and Science at Tokyo Women’s Medical University (TWMU). I graduated from Department of Engineering, Kyushu University and received Ph.D. in 2006. I then received a Research Fellowship for Yong Scientists from Japan Society for the Promotion of Science (JSPS) and performed postdoctoral research under Prof. David Grainger, Colorado State University and University of Utah, USA. My researches as a postdoc was the development of a hydrogel-based local drug delivery system and micropatterning techniques of cells and proteins. After that, I moved to TWMU and started biomaterials research for tissue engineering and regenerative medicine in 2008. My recent work is focused on skeletal muscle tissue engineering for the development of in-vitro tissue model.

Ming-Jer Tang

Ha-Rasv12 overexpression causes loss of cyclic stretch-induced perpendicular alignment in MDCK cells

 

bio

Ming-Jer Tang, M.D., Ph.D.
Distinguished Professor
Department of Physiology
National Cheng Kung University Medical College
Tainan, Taiwan

Education
1973-1980 Taipei Medical College, Taipei, Taiwan. M.D.
1983-1987 University of Michigan, Ann Arbor, Michigan. Ph.D. (Physiology)

Professional experience
1987-1988 Postdoctoral fellow, Department of Int. Medicine. University of Michigan Medical Center, Ann Arbor, Michigan. (Richard L. Tannen, M.D.)
1988-1990Postdoctoral fellow, Department of Physiology and Biophysics. University of Southern California Medical School, L.A. California. (Alicia A. McDonough, Ph.D.)
1990-1996Associate Professor, Department of Physiology, National Cheng Kung University Medical College
1996-Professor, Department of Physiology, National Cheng Kung University Medical College
1997-1998Visiting Scientist, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, Michigan. (Gregory R. Dressler, Ph.D.)
2001-2007Executive Vice Dean, National Cheng Kung University Medical College
2002-Distinguished Professor, Department of Physiology, National Cheng Kung University Medical College
2007-2011 Vice President of Academic Affairs, National Cheng Kung University
2013-2016President, Tunghai University, Taichung
2016-Director, International Center for Wound Repair and Regeneration (iWRR)
National Cheng Kung University (Funded by MOE and MOST)

Fields of specialty
Physiology, Cell and Molecular Biology, Tissue Engineering, Mechanobiology.

Tingting Tang

 

bio

Hiroaki Tateno

 

bio

Hiroaki Tateno received his Ph.D. degree in in Agricultural Science from Tohoku University in 2002. After post-doctoral fellowships at the University of Michigan (2002-2004) and the Scripps Research Institute (2004-2006), he moved to the National Institute of Advanced Industrial Science and Technology (AIST). At present he is a group leader & chief senior researcher at the Biotechnology Research Institute for Drug Discovery. He developed a high-sensitive glycan profiling technology called high-density lectin microarrays and performed comprehensive glycome analysis of human pluripotent stem cells (hPSCs). He found a novel hPSC-specific lectin probe rBC2LCN, which binds to hPSCs, but not to differentiated somatic cells. Using rBC2LCN, he developed staining, detection, and elimination methods of tumorigenic hPSCs resided in hPSC-derived cell therapy products. Recently, we analyzed the glycome of extracellular vesicles (EVs) derived from hPSCs and demonstrated that EVs reflect the cell surface glycan signatures of hPSCs. These technologies are now commercialized from a Japanese reagent company. He was awarded 2nd Bioindustry Research Award, 17th the Japanese Society of Carbohydrate Research Award, and JSBBA Award for Young Scientists. In this symposium, he will talk about the glycome of stem cells and application to regenerative medicine.

Peter ten Dijke

Bone Morphogenic proteins and their receptors in bone and cardiovascular diseases

 

bio

I, Peter ten Dijke, received my Ph.D. degree in 1991 from Wageningen University, the Netherlands, based on the identification of the third isoform of TGF-β performed at Oncogene Science, Inc., New York, USA. I did my postgraduate studies on TGF-β family receptor identification and signaling with Kohei Miyazono and Carl-Henrik Heldin at the Ludwig Institute for Cancer Research (LICR), Uppsala, Sweden. In 1994, I became a group leader at LICR and identified the inhibitory Smad7 and investigated the role of Smads as sequence specific transcriptional effectors for TGF-β family members. In 1999, I moved to the Netherlands Cancer Institute, Amsterdam, The Netherlands, and elucidated (among other things) the molecular mechanisms by with TGF-β can inhibit and promote (tumor) angiogenesis. In 2005, I moved to the LUMC, Leiden, The Netherlands. My laboratory studies the molecular mechanisms by which TGF-β family members elicit their cellular effects via (co)-receptors and intracellular SMAD effectors and performs pre-clinical/translational research in the field of cancer, vascular and musculoskeletal diseases.
Our Chemical Signaling laboratory investigates the mechanisms by which perturbations in TGF-βfamily signaling are caus-ally linked to human diseases. Using functional genetic screens we have identified E3 ubiquitin ligases and DUBs that control TGF-β signaling. We use 3-dimesional heterotypic culture systems as well as zebrafish and mouse models. Chemical biology approaches are employed to monitor and inhibit or activate selective TGF-β family signaling pathways. Our overarching aim is to find innovative ways to target perturbed TGF-β family signaling pathways for therapeutic gain.

Swee-Hin Teoh

Development of bi-axial bioreactor with mechanical and electro-magnetic signals for bone tissue engineering

 

bio

Professor Swee-Hin Teoh, School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at Nanyang Technological University (NTU) Singapore, is known for the clinical translation of 3D printed bioresorbable scaffolds which has FDA approval and implanted in more than 20,000 patients globally He has won a number of major awards such as the “Golden Innovation Award”, Far East Economic Review, and the Institute of Engineers Singapore “Prestigious Engineering Achievement Award” (2004). Majoring in Materials Engineering, Monash University, his research journey focused on translating the materials research to biomedical benefits. His research on regenerative medicine covers tissue engineering of bone and skin to biomimetic bioreactors, fish collagen, decellularized organs and artificial egg shells, with a dream to eventually translating them clinically. He has over 260 research publications and 22 patents. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. Recently he was awarded a significant grant from the Ministry of Education Singapore to develop a unique bioreactor with electromagnetic energy to study how this effect bone growth. His Web of Science Citation recorded is 8,815 and h-index is 48. He has also won numerous “Excellent Teaching Awards".

Bee Tin

Tissue engineering for oral & maxillofacial applications

 

bio

Clinical Associate Professor Goh Bee Tin is a Senior Consultant in the Department of Oral and Maxillofacial Surgery (OMS), Deputy Director (Research and Education) and Research Director at the National Dental Centre of Singapore. A/Prof Goh is also Vice- Chair, Research in the SingHealth Duke-NUS Oral Health Academic Clinical Program. A/Prof Goh is appointed Clinical Associate Professor at the National University of Singapore (NUS) Faculty of Dentistry and Adjunct Associate Professor at the Nanyang Technological University (NTU), School of Chemical and Biomedical Engineering. A/Prof Goh obtained her Bachelor of Dental Surgery from the National University of Singapore (NUS) in 1993. She then went on to specialize in the field of OMS, obtaining her Dental Fellowship with the Edinburgh Royal College of Surgeons in 1996 and Master of Dental Surgery from NUS in 1997. She was admitted as a Fellow of the Academy of Medicine, Singapore in 2000. In that same year, she was sent on a government scholarship for advanced training in cleft lip and palate and orthognathic surgery in Canada. In 2004, she furthered her training in craniofacial implantology in Sweden and the United Kingdom. She obtained a PhD in 2009 from Radboud University Nijmegen, the Netherlands for her novel research work on modular endoprosthesis for mandibular reconstruction. Her research interests are in bone tissue engineering and development of novel devices for mandibular reconstruction. She received the Osteopore Innovation Award for her work in clinical tissue engineering and the SingHealth GCEO Outstanding Clinician Researcher Award.

Joe Tiralongo

 

bio

Phong Tran

 

bio

Dr Tran is an emerging mid-career scientist with more than 50 publications, 1 granted patent, more than 1200 citations and an h-index of 15 (Google scholar). As a Chief Investigator, he has been awarded research grants totalled more than $4.5M from funding bodies such as Australian Research Council (ARC), Queensland Government, Australian Academy of Technology and Engineering and Defence Health Foundation. He is serving on the Editorial Board of the Australasian Physical & Engineering Sciences in Medicine, frequent reviewers for leading biomedical/biomaterial research journals and as a detailed assessor for ARC’s National Competitive Grants Program (NCGP).

Dr Tran has deep interest and rich experience in industry-linked biomaterials research and technology commercialization stemming from his PhD studies at Brown University (Rhode Island, USA) and his fellowship in the Department of Orthopaedic Research at Rhode Island Hospital (2005-2011). He was a co-founder of Nanoseleno – a spinoff company from Brown University to commercialize selenium nanoparticle based antimicrobial formulations and a scientific board member of Axena Technologies (RI, USA) – a start-up focusing on antimicrobial coatings of catheters.

Dr Tran moved to the University of Melbourne in late 2011 to accept the McKenzie Fellowship and formed a team of experts in polymer chemistry, microbiology and reconstructive surgery to develop antimicrobial nanocomposite materials. In 2015, he was awarded the Vice Chancellor’s Research Fellowship and moved to Queensland University of Technology where he formed and is currently leading the Interface Science and Materials Engineering group to research into the design, development and translation of biomaterials. In 2017 he was awarded the mid-career Advance Queensland Research Fellowship to work with a Queensland-based medical device company to translate his antimicrobial surface treatment and biomaterials research toward commercialization.

Dr Tran is also passionate about teaching. He has been lecturing in Biomaterials, Biophysics, Biocellular Systems and Electrodynamics. Dr Tran’s on-class demonstrations and real-life examples are highly rated by his students. Dr Tran is also a strong advocate of public outreach in science, he was featured on several media channels including ABC news https://www.abc.net.au/news/2018-12-24/christmas-prawn-shells-used-to-fi....

Kelly Tsang

 

bio

Kelly Tsang is an engineering technical leader at the Medical Devices Branch of the Therapeutic Goods Administration (TGA). He is heavily involved in the assessment of high risk medical devices and emerging tehnologies as well as monitoring device post-market performance via data analytics. Kelly received his Bachelor of Science, Bachelor of Engineering(Hons) and PhD degrees from Monash University, and has 10 years of experience in developing novel biomaterials and coatings for tissue engineering and medical device applications across leading institutes including Monash University, the CSIRO, Brigham Women's Hospital (MA, USA) and the Massachusetts Institute of Technology. Kelly was named the Fulbright Postgraduate Scholar in Science and Technology in 2011 and was one of 5 researchers recognised at the CRC Association Early Career Researcher Showcase in 2015.

Martijn van Griensven

Co-morbidities influence regeneration of critical defects in long bones

 

bio

Martijn van Griensven studied in Leiden (NL) and was trained in Hannover (D). He was appointed as full professor for experimental trauma surgery in 2002. In 2005, he became co-director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in Vienna (A). In September 2011, he was appointed as director for the department of Experimental Trauma Surgery at the Technical University of Munich (D). His research areas are related to engineering methods for the musculoskeletal system using stem cells of different sources, biomaterials, gene therapy and mechanical loading. He is always striving to translate this to the clinic. His most recent grants deal with engineering the enthesis (ligament-to-bone transition), oxygen measurement in tissue engineered constructs and also with miRNA usage for diagnostics and therapeutics. He has published 283 peer reviewed original papers, 28 book chapters and he has edited 4 books. He has 2 patents. His h-factor is 43 (WoS)/52 (Scholar). He has received several awards for his work, among others the young scientist award from the World Biomaterials Society. He serves currently on the council of TERMIS-EU as well as of the German surgical research society.

Andre van Wijnen

Osteogenic Programming by Inhibiting Epigenetic Suppression

 

bio

Dr. Andre van Wijnen received pre-doctoral training in molecular biology and biochemistry at the University of Utrecht, Netherlands, in conjunction with the University of Florida, Gainesville, FL. He graduated with a doctoral degree in Biomedical Sciences from the University of Massachusetts Medical School where he ascended the academic track to the rank of Professor. In 2012, he started a new translational research laboratory at Mayo Clinic focusing on musculoskeletal disorders, pharmacotherapies and stem cell therapies. From a fundamental perspective, his research group focuses on projects that examine biological and mechanistic questions on the regulation and deregulation of skeletal tissue development using state-of-the-art approaches including genomics, epigenomics, proteomics, and mouse genetics.

Shyni Varghese

Tumor-on-chip platforms to study heterotypic cell-cell interactions and T cell recruitment

 

bio

Shyni Varghese, Ph.D., is a Professor of Biomedical Engineering, Mechanical Engineering & Materials Science, and Orthopaedics Surgery at Duke University. She is the inaugural MEDx Investigator at Duke University. Prior to moving to Duke, she was a Professor of Bioengineering at University of California, San Diego. Dr. Varghese’s research covers a broad range of topics including stem cells, biomaterials, biologically inspired systems, and regenerative medicine. Her research activities have resulted in over 100 publications and 12 patent disclosures. Examples of ongoing research activities in her laboratory involve developing functional biomaterials such as self-healing hydrogels and biomineralized matrices; technologies to improve cell-based therapies including stem-cell differentiation, cell transplantation, activating endogenous stem cells, and engineered functional tissue grafts; and organ-on-a-chip technologies. She is currently serving as an Associate Editor of Biomaterials Science (an RSC journal).

Krasimir Vasilev

 

bio

Professor Vasilev completed his PhD at the Max-Planck Institute for Polymer Research in Mainz, Germany in 2005. He is currently an NHMRC Fellow and a Humboldt Fellow, and a Full Professor at the University of South Australia. He is the author of more than 180 publications, 5 patents and has been awarded in excess of 20 million dollars of research funding. His work results in translation of research discoveries to tangible commercial outcomes such as device for bladder cancer diagnostics and antibacterial surface for hip and knee implants, both technologies being currently industrialized with commercial partners. For his work, he has received various honors and awards such as the John A. Brodie Medal for achievements in Chemical Engineering in 2016 and the International Association of Advanced Materials Medal (IAAM medal) for contributions to the field of Advanced Materials in 2017. In 2017, he was elected a Fellow of the Royal Society of Chemistry (FRSC).

Gordon Wallace

3D Printing with Living Cells – Tackling Medical Challenges

 

bio

Professor Gordon Wallace is involved in the design and discovery of new materials for use in Energy and Health. In the Health area this involves using new materials to develop biocommunications from the molecular to skeletal domains in order to improve human performance. In the Energy area this involves use of new materials to transform and to store energy, including novel wearable and implantable energy systems for the use in Medical technologies. In order to facilitate the creation of functional devices from fundamental discoveries he has pioneered the development of 3D additive fabrication (including 3D printing) using advanced materials.

He is committed to fundamental research and the translation of fundamental discoveries into practical applications. He is a passionate communicator, dedicated to explaining scientific advances to all in the community from the lay person to the specialist.

He was appointed as an Officer of the Order of Australia 26 January 2017.

Beat Walpoth

 

bio

Guocheng Wang

 

bio

Received his Ph.D. diploma in Materials Science at Shanghai Institute of Ceramics, Chinese Academy of Sciences (CAS), in 2009. From 2009-2012 he did post-doctoral research at the University of Sydney, in the Biomaterials and Tissue Engineering research Unit in Faculty of IT and Engineering then he moved to Spain for two years as a research associate in CIC biomaGUNE (San Sebastian, Spain). Since 2015, he has been the leader of “Biomaterials and Cell Behavior Regulation” group named at Center for Human Tissues and Organs Degeneration in Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, CAS. His main research interest includes biomaterials for hard tissue replacement and regeneration (dental implant, surface modification of bone implants and bone scaffolds), cell/microbial behavior regulation based on material surface properties manipulation, and biomorphic silica-carbonates. He has published more than 40 peer-reviewed articles in leading journals in the field, e.g. Biomaterials, Journal of Material Chemistry, ACS Applied Materials & Interfaces; Acta Biomaterialia etc. and has one book chapter published by the Woodhead Publishing. In 2015, he was rated Shenzhen Overseas High-Caliber Personnel. From July 2015 to present, he has won more than 2 million Australian dollars research funding from Chinese Research Funding Agencies. He was the leading guest editor for one of the special issues of BioMed Research International, member of Youth Committee of Metal Material Branch in Chinese Biomaterials Society.

Guocheng Wang

 

bio

Lin Wang

 

bio

Dr. Lin Wang is currently the Professor/Director of the Research Center for Tissue Engineering and Regenerative Medicine at Union Hospital, Huazhong University of Science and Technology (Wuhan, China). She is interested in solving medical problems using multi-interdisciplinary approaches. In recent years, she has focused on research and development of naturally derived biomaterials and their applications in tissue regeneration and cancer therapy. Her findings during the years have laid foundation for future clinical translation. She and her research team reported the potential value of sericin biomaterial in tissue repair and regeneration. Her research not only developed new types of biomaterials but also provided important rationale for their medical applications. She utilized these biomaterials for central and peripheral nerve regeneration, cardiac tissue repair as well as cartilage and skin repair and developed a number of novel multi-functional biomaterials, such as scaffolds, nerve guidance channels and drug delivery vehicles. With this work, she opened up possible new medical applications for sericin for tissue regeneration and cancer therapy. She was awarded the "Women in Science award" for recognition of women scientists in China and elected as “the Yangtze River Scholar ” by the Ministry of Education.

Xiaoqin Wang

Silk-based nano- and microencapsulation for controlled drug release

 

bio

Education
1987 - 1991 BSc in microbiology, Shandong University
1995 - 1998 MS in molecular biology, Peking Union Medical College
1998 - 2004 PhD in biochemistry, University of Groningen, the Netherlands
Employment
08/1991-07/1995 Research scientist, Harbin Medical Group
01/2009-12/2011 Research associate, Biomedical Engineering Department, Tufts University
01/2012- present Research Assistant Professor, Biomedical Engineering Department, Tufts University
11/2011- present Professor, National Engineering Laboratory for Modern Silk, Soochow University, China
05/2013 – present president, chief scientist, Simatech Inc., Soochow China
Research interests
(a) Biomedical applications of naturally derived biomaterials
(b) Controlled drug delivery
(c) Tissue engineering

Xiaoqin Wang is a senior scientist with his education and training background in microbiology, biochemistry, biomaterials, and biomedical engineering. His research focus is on biopolymer engineering using naturally derived biodegradable polymers, such as silk fibroin, to develop novel carrier systems for the delivery of therapeutics and cells for biomedical applications. He has published over 50 peer-reviewed articles and more than 30 US and Chinese patents. He is also involved in the founding and development of several biotech companies in the US and China. Dr. Wang is currently a professor at Soochow University in China.

Zheng Wang

 

bio

Dr. Zheng Wang is currently the Professor of Surgery, Department of Gastrointestinal Surgery, and Associate Director of the Research Center for Tissue Engineering and Regenerative Medicine at Union Hospital, Huazhong University of Science and Technology (Wuhan, China). He received his MD from Tongji Medical College and PhD from Duke University with postdoctoral training in Stanford University and Duke University. His current research interests mainly lie in developing new biomaterials and applying them for designing novel strategies for improving cancer diagnosis and therapy. Through combining cell biology and bioengineering concepts and technologies, his recent work has been directed towards cancer bioengineering. Using various biomaterials (including silk sericin) to biochemically and physically modulating tumor extra- and intra-cellular microenvironment, his research team has developed several effective strategies for combatting cancer multidrug resistance, eradicating tumor repopulation, and preventing metastasis, which result in a number of patents with clinical translational potential. He is an active member in major medicine and engineering professional societies in China. He has won several prestigious national and regional scientific awards for recognition of his work.

Tony Weiss

 

bio

Professor Tony Weiss is the McCaughey Chair in Biochemistry, Professor of Biochemistry & Molecular Biotechnology, and Leader of the Tissue Engineering & Regenerative Medicine Node at the Charles Perkins Centre, and member of the Bosch Institute and Sydney Nano Institute at the University of Sydney.

He is President-Elect (global) of the Tissue Engineering and Regenerative Medicine International Society, immediate past President of the Matrix Biology Society of Australia and New Zealand and was elected Chair of Tissue Engineering and Regenerative Medicine International Society for Asia-Pacific.

Professor Weiss has pioneered research into human tropoelastin (the protein building-block that gives tissue its elasticity), discovered how to assemble it into synthetic elastin biomaterials that accelerate and improve the repair of scars and wounds, and commercialised his discoveries. He is on the Editorial Boards of 10 international scientific journals, and an inventor on 95 awarded patents in 18 patent families.

His prizes include the Eureka Prize for Innovation in Medical Research, NSW Premier’s Prize for Science & Engineering Leadership in Innovation, Vice Chancellor’s Award for Excellence, Innovator of Influence Award, RACI Applied Research Medal, FAOBMB Entrepreneurship Award, MBSANZ Barry Preston Prize, ASBTE Research Excellence Award, Australian Innovation Challenge Prize, and the Order of Australia.

Cuie Wen

 

bio

Cuie joined RMIT University as a Professor of Biomaterials Engineering in 2014 and she has been appointed Distinguished Professor in 2015. She was Professor of Surface Engineering at Swinburne University of Technology from 2010 to 2014. She worked at Deakin University from 2003 to 2010 as Research Fellow, Senior Researcher and Associate Professor.
Cuie has published more than 370 peer reviewed articles with an h-index 46 and citations over 8400 (Google Scholar). Cuie has supervised 10 postdoctoral research projects, 25 post graduate students to completion. She is an editorial board member for the journals of Acta Biomaterialia, and Bioactive Materials. Her research interests include new biocompatible titanium, magnesium, iron, zinc and their alloys and scaffolds for biomedical applications, surface modification, nanostructured metals, alloys and composites, metal foams and nanolaminates.

Cuie Wen

Titanium gyroid scaffolds manufactured by selective laser melting for bone implant applications

 

bio

Mark Wilcox

Development of antimicrobial contact lenses

 

bio

I am a medical microbiologist, and completed my PhD at Manchester University in 1987. My laboratory focuses on contact lens research, specifically understanding the etiology of adverse events and comfort during contact lens wear. My research includes adhesion and biofilm formation of ocular pathogenic microbes (most notably Pseudomonas aeruginosa) and development of novel antimicrobial surfaces. This research involves the study of microbial pathogenesis, and mammalian tissue responses to microbes and biomaterials. In particular I have developed several antimicrobial compounds that can be attached to polymers and metals to provide antimicrobial coatings for medical devices. These have been tested in laboratory and animal models, and one of these - contact lenses with the peptide Mel4 coated onto them - has progressed to a Phase II/III clinical trial that completed in Dec 2017. I am a Fellow of the Australian Society for Microbiology, Fellow of the British Contact Lens Society, Fellow of the American Academy of Optometry, and Fellow of the Association for Research in Vision and Ophthalmology.

May Win Naing

Advanced Bioreactor for manufacturing of next generation cell therapies

 

bio

Dr May Win Naing heads the Bio-Manufacturing Programme (BMP) at Singapore Institute of Manufacturing Technology (SIMTech), Agency for Science, Technology & Research (A*STAR), Singapore. Dr Naing received her first degree in Mechanical Engineering from Nanyang Technological University, Singapore in 2002 and pursued her PhD in the same university with a thesis focused on Tissue Engineering, graduating in 2006. Since then, she has been working in medical technology innovation, in both industry and academia. Prior to joining A*STAR in 2013, she was a Translational Research Scientist at the EPSRC Centre for Manufacturing of Regenerative Medicine at Loughborough University, UK, and has also taken on R&D and technical marketing roles in the medical technology industry, specialising in spinal implants and instrumentations. Through these positions, she has gained experience in medical technology R&D and manufacturing as well as regulatory submission and market approval requirements for markets within the Asia Pacific region. Having worked in both academic and industry settings in Singapore and abroad, she is committed to translation of technology into the clinic and the market. Her current research interest centres on scale-up manufacturing of biological products such as tissue scaffolds and cell therapies for applications in regenerative medicine, toxicity testing and consumer industries.

Steve Wise

In vivo evaluation of next generation vascular materials

 

bio

Dr Wise, BSc (Hons 1, University Medal, UWS 2001), PhD (USyd 2006) is leader of the Applied Materials Group at the Heart Research Institute (HRI) and Conjoint Clinical Senior Lecturer at the Central Clinical School of the University of Sydney. His research group focuses on the construction of platform biomaterials broadly applicable to soft tissue, bone and vascular repair applications and includes aspects of bioengineering, in vitro cell and hemocompatibility assays and transition to in vivo testing in established small and large animal models. His work has contributed to the development of (i) novel ECM-inspired modification of metal substrates relevant to improved vascular stents, (ii) new synthetic vascular graft materials engineered for a combination of mechanical and biological properties and iii) enhanced understanding of the cell-biomaterial relationship and subsequent scaffold remodelling. He has a strong publication track record including 61 peer-reviewed papers, 1 book chapter, 3 awarded and 1 PCT patents. He has attracted >$3.2M as lead CI, including recently awarded ARC linkage, NHMRC Project and NHMRC Development Grants.

Julie Wixey

Protecting the newborn brain using stem cell treatment

 

bio

Dr Julie Wixey is a Postdoctoral Researcher at the Perinatal Research Centre, The University of Queensland Centre for Clinical Research. She completed her PhD in Neuroscience at The University of Queensland in 2013. Her research aims to better understand the mechanisms of brain injury in growth restricted newborns. Growth restriction has important effects on the developing fetal brain and is associated with high rates of disabilities in children, ranging from intellectual and behavioural issues to cerebral palsy. Currently no treatment exists to prevent or even reduce brain injury in these babies. She has recently discovered inflammation is a key mechanism of brain injury in the growth restricted newborn. Her research is currently focusing on trialing therapies that reduce inflammation and concurrently provide neuroprotection to reduce long-term disabilities in these growth restricted babies.

Dr. Raymond CB Wong

 

bio

Dr Raymond CB Wong, Ph.D. is a Principal Investigator at the Centre for Eye Research Australia (CERA), the University of Melbourne in Australia and a Guest Professor at Shenzhen Eye Hospital in China. He is a stem cell biologist with 16 years of research experience, specialising in cellular reprogramming, pluripotent stem cells and neural/retinal differentiation. Dr Wong completed his PhD in stem cell biology at Monash University and was awarded a California Institute of Regenerative Medicine fellowship to pursue overseas postdoctoral training in University of California Irvine (USA), and a Visiting Fellow Award to train in National Institutes of Health (USA). In 2013, Dr Wong joined CERA with the support of a Cranborne Foundation Fellowship and subsequently established the Cellular Reprogramming Unit with the support of a MAWA Fellowship. Currently Dr Wong’s research focuses on understanding the genetic signals that define retinal cells, and using cell reprogramming and stem cell technologies to study retinal diseases and regenerative medicine.

Tim Woodfield

3D Bioassembly for Regenerative Medicine of Musculoskeletal Tissues

 

bio

Tim Woodfield is Associate Professor of Regenerative Medicine at the University of Otago Christchurch, New Zealand. He leads the CReaTE Group within the Department of Orthopaedic Surgery and is Director of the Otago Centre for Bioengineering & Nanomedicine. He holds a prestigious Rutherford Discovery Fellowship and is Principal Investigator within the Medical Technologies Centre of Research Excellence (CoRE). He holds an adjunct Assoc Professor at Queensland University of Technology, Australia. His research is investigating stem cell and biomaterial-based strategies for musculoskeletal tissue regeneration and their application in the clinical translation of orthopaedic medical devices & cell-based therapies. His research technology platform involves complex 3D Biofabrication and Additive Manufacturing of biomaterial scaffolds and medical devices applied to regenerative medicine of cartilage and bone, including: novel bio-ink/bio-resin development, advanced 3D tissue culture models and high throughput screening. He has published over 100 peer reviewed journal articles, book chapters and published conference proceedings, and acted as coordinator of the recent European Commission ‘skelGEN’ consortia project. He has attracted over NZ$23 million in competitive research funding as a Principal or Named Investigator through grants from the Royal Society of New Zealand, Ministry of Business Innovation & Employment, Health Research Council, AO Foundation. He is past President of the Australasian Society for Biomaterials & Tissue Engineering (ASBTE) and is currently Executive Board member and Vice President of the International Society for Biofabrication (ISBF). He sits on the TERMIS-Asia Pacific Council, and is Editorial Board member for Biofabrication, APL Bioengineering, and Frontiers in Bioengineering & Biotechnology.

Chengtie Wu

 

bio

Chia-Ching Wu

Mechanical and material interfaces on differentiation dynamics for adipose-derived stem cells

 

bio

Wei Fang Wuhan

Stable ectopic chodrogenesis by chondromodulin-1 up-regulation

 

bio

A clinician and researcher of temporomandibular joint disorders.

Yin Xiao

 

bio

Akiko Yamamoto

 

bio

Dr. Akiko Yamamoto is a managing researcher of the National Institute for Materials Science (NIMS), Japan. She is an Associate Professor (Cooperative Graduate School Program) at University of Tsukuba from 2008. She was a Visiting Professor of the WUT-NIMS Joint Graduate Program at Warsaw University of Technology during 2016-2011 as well as Kanazawa Institute of Technology during 2013-2004. She stayed at the Center for Cell Engineering, University of Glasgow during 2000-1999. She was awarded her Ph.D (Engineering) from Kyoto University at 1998. She joined to the National Research Institute for Metals, which was merged with the National Institute of Research for Inorganic Materials to form NIMS at 2004, after she was awarded her Masters’ Degree in Natural Science from International Christian University at 1993.
Her research interests include metallic biomaterials including biodegradable metals, biomolecular/cellular response to material surface, and materials corrosion/degradation properties under biological environment.

Fuhua Yan

 

bio

Professor Fuhua Yan is the chief physician, Ph.D supervisor and Vice Dean of Nanjing Stomatological Hospital, Medical School of Nanjing University. He is also the President-elect of Periodontology of Chinese Stomatological Association and the Vise-President of Jiangsu Stomatological Association. His main research areas include the tissue engineering and periodontal regeneration, the relationship between periodontal diseases and systemic diseases, implant restoration with periodontal diseases et cetera. To date, he has presided and finished 16 scientific research projects which include provincial, ministerial and national levels (including 6 projects of National Natural Science Foundation of China), moreover, he has published more than 100 papers ethier in domestic or foreign academic journals (including 60 SCI papers). Now, he is hosting 4 scientific research projects which include 2 higher level projects (National Natural Science Foundation of China). He has also translated or participated in the editing of 18 academic monographs and won a second prize of Provincial Scientific and Technological Progress Award, and a second prize of Science and Technology Award of Chinese Stomatological Association for his achievements. To date, he has supervised 21 PhD and 41 MSc students to graduation and is currently leading a team of 5 PhD and 6 MSc candidates.

Jen Ming Yang

Development of magnetic stimuli drug release system based on dendrimer/gadonilium iron oxide complex

 

bio

Jen Ming Yang is currently a Professor in department of Chemical and Materials Engineering at Chang Gung University, Research Fellow (joint appointment) of Chang Gung Memorial Hospital, Taoyuan, and Council of Tissue Engineering and Regenerative Medicine International Society-Asia-Pacific Chapter (TERMIS-AP). Prof. Yang received his PhD Degree in Polymer Science at National Tsing Hua University in 1990. From 1990 to 1991 he continued his studies at the University of California at Berkeley, and achieved his Postdoctorate degree in Polymer Science. From Aug, 2002 to Jul. 2003 he had been a visiting scholar of Prof. Langerâs group at Massachusetts Institute of Technology. Currently, Prof. Yangâs field of research encompasses Polymer Science, Membrane, and Biomaterials. He has been board member of some journals, societies and conferences. He has also presented keynote and invited speeches at many conferences and hosted international conferences. The 2019 Cross Strait Forum on Biomedical Materials (2019CSFBM), 19th Asian BioCeramics Symposium (2019ABC) and 2019 International Symposium of Materials for Biomedical Application (2019 ISMBA) will be held in Chang Gung University, Taoyuan, Taiwan, ROC. On behalf of the conference, Prof. Yang would like to cordially invite you to participate in the forthcoming symposium from 2019/12/7-11.

Lei Yang

 

bio

Lei Yang is a professor and the Associate Chair of School of Materials Science and Engineering at Hebei University of Technology, Tianjin, China. He received Ph.D. in Engineering and M.S. in Innovation Management and Entrepreneurship from Brown University, USA, and both M.E. and B.E. in Materials Science and Engineering from Tsinghua University, PR China. He has published over 50 papers in high-profile journals like Nature Biomedical Engineering and authored 2 books by Elsevier. His research has also generated more than 30 Chinese patent applications (16 authorized) and 2 US patent applications. He serves as the Associate Editor-in-Chief of International Journal of Nanomedicine. He is the recipient of numerous awards, including the International Society of Orthopaedic Surgery and Traumatology (SICOT) Basic Research Award (2017), Excellent Young Scholar from the National Natural Science Foundation China (2016), the 2nd place in the China Innovation and Entrepreneurship Competition (2015), the US 125 Fresh Face Young Scientist from Sigma Xi (2011), PhD Award for Outstanding Research from the US Society For Biomaterials (2011), and Graduate Student Silver Award from the US Materials Research Society (2010).

Qiang Yang

Intervertebral disc regeneration

 

bio

Chief surgeon Qiang Yang graduated from Shandong University, and received bachelor degree in clinical medicine and master degree in surgery in 2002 and 2005 respectively. He received the M.D. and Ph.D. degree from orthopedics department of Chinese PLA General Hospital in 2008. He has been working in Tianjin Hospital, China from 2008 to now and has served successively as house surgeon, surgeon-in-charge, associate chief surgeon and chief surgeon. In the intervening years, he respectively completed two short-term trainings as a visiting research scientist at Portugal in 2008 and Queen Mary Hospital of Hong Kong in 2016. Now, he is the director of spinal ward 1 in Tianjin Hospital. Professor Yang has long been engaged in the research of tissue engineering and regenerative medicine, which involving articular cartilage and intervertebral discs. He has published more than ten SCI papers as the first/corresponding author with the highest impact factor of 8.8. He has presided over a number of national scientific research projects. He currently serves as the member of standing committee of basic science group, orthopedics branch, Chinese Medical Association and the national youth committee member of Chinese Association of Orthopaedic Surgeons (CAOS).

Yunzhi Peter Yang

 

bio

Yunzhi Peter Yang, Ph.D., Associate Professor with tenure of Departments of Orthopedic Surgery, Materials Science and Engineering (by courtesy), and Bioengineering (by courtesy) at Stanford University. He earned a doctorate in biomedical engineering, M.E. and B.S. in inorganic materials from Sichuan University in Chengdu, China. Then he has completed two postdoctoral fellowships, first in China, then at the University of Texas Dental School in San Antonio. Yang’s research interests are in the areas of bio-inspired biomaterials, medical devices, and 3D bioprinting for musculoskeletal tissue engineering. Yang’s research leads to more than 100 peer-reviewed journal papers, more than 30 active patents and patent applications, multiple technology licensing, and a few commercially available research tools. His research program has been funded by US federal government, non-profit foundations, global industry leaders, and philanthropists. He also serves on four prestigious journal editorial boards. He has received numerous research and teaching awards including the March of Dimes Birth Defect Foundation Award, the Wallace H. Coulter Foundation Translational Award, the NIH Star Award, and the 2018 TechConnect Innovation Award for 3D printing. His research in synthetic bone grafts and stem cells has been featured in New York Times, Telegraph, and TV stations.

Zhimou Yang

 

bio

Zhimou Yang, born 1978 in Guangdong Province, China. Dr. Yang received his BS from Nanjing University in 2001. He obtained his PhD in 2006 from the Hong Kong University of Science and Technology under the supervision of Professor Bing Xu. Before starting his independent research at Nankai University in March 2009, he was a postdoctoral fellow with Prof. Matthew Bogyo at Stanford Medical School. His research interests focus on biomedical applications of peptide-based hydrogels including hydrogels of drug-peptide amphiphiles for drug delivery, hydrogels of bioactive peptides for tissue engineering, and hydrogels as vaccine adjuvants, etc. He has published around 100 corresponding authored papers in the field of peptide self-assembly. He obtained the National Science Fund for Distinguished Young Scholars from National Natural Science Foundation of China in 2018.
Lab homepage: http://yang-lab.org

Adam Ye

 

bio

Ling Ye

Dual-therapeutic Hydrogels with Sequential Release Microcapsules for Regenertaion of Dental Pulp

 

bio

My research interests are dental pulp repair and regeneration. Focused on MSCs fate determination mechanism and tissue engineering application.

Kelvin Yeung

Advanced Metallic Biomaterials for musculoskeletal disease treatments

 

bio

Dr. Kelvin Yeung is passionate in orthopaedic biomaterial research for about 20 years. His major research areas cover from the development of orthopaedic biomaterials, 3D bio-printing as well as musculoskeletal tissue engineering. He trained as materials scientist in his bachelor degree and then orthopaedic scientist in HKU Medical Faculty for his master degree and PhD, respectively. He is currently tenured associate professor in the Department of Orthopaedics and Traumatology, The University of Hong Kong. His h-index is 44 with more than 6,000 citations. He has also been ranked as the World’s Top 1% Scientists in the field of biomaterials by Clarivate Analytics’s Essential Science Indicators (ESI) since 2014. In addition to his more than 200 peer-reviewed SCI journal papers published and 38 filed full patents in various countries, he has co-founded the OrthoSmart Limited together with two senior colleagues so as to translate their research findings to clinical use. He also serves as interim CEO of this startup company. Furthermore, he has been invited to be the consultants of few medical device and biomaterials incorporations.
During these years, he had received numbers of award and scholarship from local and regional competitions such as Young Scientist Award 2005 and Young Engineer Award 2009, respectively. The total amount of grants and sponsorships directly arising from his projects in PI and Co-PI capacity has been over HK$68M. Additionally, he has supervised 8 PhD and 11 MPhil students since 2006. Furthermore, he obtained 18 prizes and awards from local and international competitions and conferences. Dr Yeung has also become an active member and actively served different executive positions in local and international academic bodies. Apart from these professional positions, he has been appointed as Deputy Master of HKU Lap-Chee College so as to oversee the student education programs there. He has also participated himself into the executive positions in alumni bodies and patient benefit groups.

James Yoo

Biofabrication: Translational Pathway to the Clinic

 

bio

Dr. Yoo is Professor and Associate Director of the Wake Forest Institute for Regenerative Medicine (WFIRM), with a cross-appointment to the Departments of Urology, Physiology and Pharmacology, and the Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences. Dr. Yoo's research efforts have been directed toward the clinical translation of tissue engineering technologies and cell-based therapies. Dr. Yoo's background in cell biology and medicine has facilitated the transfer of several cell-based technologies from the bench-top to the bedside. A few notable examples of successful clinical translation include the bladder, urethra, vagina, and muscle cell therapy for incontinence. Dr. Yoo has been a lead scientist in the bioprinting program at WFIRM, and has been instrumental in developing skin bioprinting and integrated tissue and organ printing (ITOP) systems for preclinical and clinical applications.

Marcy Zenobi-Wong

To Print or Not To Print: Pre-clinical Studies of Engineered Cartilage

 

bio

Dr. Marcy Zenobi-Wong is an Associate Professor of Tissue Engineering and Biofabrication at ETH Zürich, Switzerland. She obtained her PhD from Stanford University and then did a post-doctoral fellowship in the Orthopaedic Research Laboratories, University of Michigan. In 2012, she moved to the Department of Health Sciences & Technology at ETH Zürich. The Zenobi-Wong research group is focused on the development of advanced biomaterials for tissue regeneration using biofabrication technologies including bioprinting, two-photon polymerization, casting and electrospinning. Dr. Zenobi-Wong is the author of over 75 peer-reviewed publications and co-inventor on four licensed patents. She is currently Vice President of the Swiss Society for Biomaterials and Regenerative Medicine and general secretary for the International Society of Biofabrication (ISBF). She serves on the editorial board for Biofabrication and Advanced Healthcare Materials.

Shengmin Zhang

Micro/Nano-CaP Biomimetic Scaffolds Induce Multi-tissue Regeneration

 

bio

Xin Zhao

 

bio

Xin Zhao

 

bio

Dr. Xin Zhao is an assistant professor at the Department of Biomedical Engineering, the Hong Kong Polytechnic University, Hong Kong SAR, China. She received her PhD in Biomaterials and Tissue Engineering from University College London (UCL), UK (2010). Prior to her current position, Dr. Zhao worked as a postdoctoral research fellow at Harvard University, Harvard-MIT Health Science & Technology (HST) and School of Engineering of Applied Sciences (SEAS) and as an associate professor at Xi’an Jiaotong University (XJTU). Dr Zhao is dedicated to interdisciplinary research involving topics such as biomaterials, tissue engineering, drug delivery, cell micro-environment and microfluidics. She uses multi-disciplinary approach including material science, nanotechnology, cell biology and microfluidics to generate tissue-engineered organs and control cell behaviors for addressing clinical problems. So far she has published over 70 peer-reviewed journal articles and book chapters and holds two national patents. Her work has been published in leading journals of the biomaterials field such as Chemical Reviews, Materials Today, Advanced Functional Materials, Angewandte Chemie International Edition, Biomaterials, Small, Theranostics, etc. Since she joined PolyU two years ago, she has attracted 6 grants as PI or co-I (~ 8 million HKD). She represents HK and participates in the prestigious APRN Fellowship program. Moreover, she has edited a book, authored in 5 book chapters. She has also chaired sessions or delivered keynote speeches at >10 international conferences, works as a guest editor for Drug Discovery Today, and serves as reviewer for PNAS, ACS Nano, etc.

Minghao Zheng

Long-term outcomes of MACI inform the importance of functional barrier structure of osteochondral unit

 

bio

Professor Minghao Zheng is currently Associate Dean of the Faculty of Health and Medical Science of the University of Western Australia. He graduated as Bachelor of Medicine at Shantou University in 1983, Master of Medicine at Sun Yet Sen University of Medical Science in 1987, PhD in 1993, Doctor of Medicine (MD) in 2000 at the University of Western Australia. He is fellow of the Royal College of Pathologists, UK and the Royal College of Pathologists of Australasia. He is the founder of regenerative medicine company Orthocell Ltd (ASX:OCC) in Australia and Chung Kong Lecturing Professor at Zhejiang University, China. He is currently member of Faculty 1000 Prime and Associate Editor of Stem Cell Research and Therapy. He has published over 200 papers and holds 7 patents. He has over 6300 citation with H index of 46.

Yufeng Zheng

 

bio

Dezhong Zhou

Nonviral gene therapy in tissue engineering

 

bio

Dr. Zhou is currently a full professor in School of Chemical Engineering and Industry, Xi’an Jiaotong University, China. Dr Zhou’s research interest has covered a wide range of topics including hyperbranched and/or cyclized polymer synthesis and structure control via controlled/living polymerisation techniques (ATRP, RAFT, ROP) and click chemistry, DNA/RNA/drug/protein delivery, Injectable hydrogels for stem cells encapsulation and delivery. Dr. Zhou has published 48 research articles in peer-reviewed scientific journals and secured several prestigious research funding. He has presented his research findings at multiple national and international conferences.

Yinghong Zhou

 

bio

Dr Yinghong Zhou is an NHMRC Early Career Fellow within the Bone and Joint Disorders Program at the Institute of Health and Biomedical Innovation. Dr Zhou obtained her PhD in Medical Engineering from the Queensland University of Technology (QUT) in December 2013. Dr Zhou seeks to understand the mechanisms for bone repair and regeneration, with a particular interest in stem cell therapy and biomaterial application. Much of her past and current research work has utilised animal models to investigate the pathophysiology and treatment of bone-related diseases. She has recently been awarded a prestigious Endeavour Research Fellowship (2017) for a collaborative project on dissecting the role of DMP1 in cell transformation from chondrocytes to bone cells at Texas A&M University College of Dentistry. Dr Zhou was appointed as the Coordinator/Acting Deputy Director of the Australia–China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM) in 2013 and has worked in the role since.

Donghui Zhu

 

bio

Dr. Donghui (Don) Zhu is the Associate Professor and Director for Graduate Program in Biomedical Engineering at University of North Texas, USA. Dr. Zhu earned his Bachelor degree at East China University of Technology and Science, and Doctorate in Bioengineering at the University of Missouri-Columbia. His Ph.D. work focused on neuro-engineering for treatment of neurological and neurovascular disorders like Alzheimer’s disease. Following his Ph.D., Dr. Zhu trained at University of Rochester medical center on regenerative medicine for vascular applications. He then became an Assistant Professor in 2010 where his research focused on novel biodegradable metallic materials for tissue engineering and regeneration. Dr. Zhu moved to Texas in 2016 as an Associate Professor to continue his research in innovative biomaterials and regenerative medicine. Currently he has a research interest in biomaterials, cardiovascular diseases, musculoskeletal disorders, as well as neuroscience and engineering. He has secured over $6 million total federal research funding in the past a few years, co-authored more than 70 peerreviewed journal articles and book chapters. Dr. Zhu also serves as editor or on editorial boards of several scientific journals and numerous grant review panels including NIH, NSF, and NASA.

Xiaohui Zou

 

bio

Dr. Xiaohui Zou received her Ph.D. degree from National University of Singapore in 2006 and currently works as professor in the First Affiliated Hospital of Zhejiang University. She is focusing on repair and regeneration of soft tissue by natural biomaterials and stem cells. She leaded the completion of a multi-center randomized clinical trials on the basic and translational studies of silk materials for tissue repair (Adv Healthcare Materials, 2017). By using of single-cell analysis techniques, her research group obtained single-cell transcriptome data sets of uterine epithelial cell development, revealing uterine development and its sequential molecular mechanism (Stem Cell Reports, 2017). She published more than 30 original academic papers in the field of regenerative medicine including Biomaterials, Tissue Engineering, Stem Cells et al.. She has received first prize on the Science and Technology Progress Award (2012).